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In preparation for a legal implementation of EU-regulation 1829/2003, the Norwegian Environment 
Agency has requested the Norwegian Food Safety Authority to give final opinions on all genetically 
modified organisms (GMOs) and products containing or consisting of GMOs that are authorized in the 
European Union under Directive 2001/18/EC or Regulation 1829/2003/EC within the Authority’s 
sectorial responsibility.  The Norwegian Food Safety Authority has therefore, by letter dated 13 
February 2013 (ref. 2012/150202), requested the Norwegian Scientific Committee for Food Safety 
(VKM) to carry out scientific risk assessments of 39 GMOs and products containing or consisting of 
GMOs that are authorized in the European Union. The request covers scope(s) relevant to the Gene 
Technology Act. The request does not cover GMOs that VKM already has conducted its final risk 
assessments on. However, the Agency requests VKM to consider whether updates or other changes to 
earlier submitted assessments are necessary. 
 
The insect-resistant and herbicide-tolerant genetically modified maize Bt11 x MIR604 x GA21 
(Unique Identifier  SYN-BTØ11-1 x SYN-IR6Ø4-5 x MON-ØØØ21-9 ) from Syngenta Seeds  is 
approved under Regulation (EC) No 1829/2003 for food and feed uses, import and processing since  
22 December 2011 (Commission Decision 2011/893/EC).  
 
Genetically modified maize Bt11 x MIR604 x GA21 has previously been risk assessed by the VKM 
Panel on Genetically Modified Organisms (GMO), commissioned by the Norwegian Food Safety 
Authority  and the Norwegian Environment Agency related to the EFSAs public hearing of the 
application EFSA/GMO/UK/2008/56 in 2008 (VKM 2008a). In addition, Bt11, MIR604 and GA21 
has been evaluated by the VKM GMO Panel as single events and as a component of several stacked 
GM maize events (VKM 2005a,b,c, 2007, 2009a,b,c,d, 2010, 2011, 2012a,b,). 
 
The food/feed and environmental risk assessment of the maize Bt11 x MIR604 x GA21 is based on 
information provided by the applicant in the application EFSA/GMO/UK/2008/56 and scientific 
comments from EFSA and other member states made available on the EFSA website GMO Extranet. 
The risk assessment also considered other peer-reviewed scientific literature as relevant.   
 
The VKM GMO Panel has evaluated Bt11 x MIR604 x GA21 with reference to its intended uses in 
the European Economic Area (EEA), and according to the principles described in the Norwegian Food 
Act, the Norwegian Gene Technology Act and regulations relating to impact assessment pursuant to 
the Gene Technology Act, Directive 2001/18/EC on the deliberate release into the environment of 
genetically modified organisms, and Regulation (EC) No 1829/2003 on genetically modified food and 
feed. The Norwegian Scientific Committee for Food Safety has also decided to take account of the 
appropriate principles described in the EFSA guidelines for the risk assessment of GM plants and 
derived food and feed (EFSA 2011a), the environmental risk assessment of GM plants (EFSA 2010) 
and selection of comparators for the risk assessment of GM plants (EFSA 2011b).  
 
The scientific risk assessment of maize Bt11 x MIR604 x GA21 include molecular characterisation of 
the inserted DNA and expression of novel proteins, comparative assessment of agronomic and 
phenotypic characteristics, nutritional assessments, toxicology and allergenicity, unintended effects on 
plant fitness, potential for gene transfer, interactions between the GM plant and target and non-target 
organisms and effects on biogeochemical processes.  
 
It is emphasized that the VKM mandate does not include assessments of contribution to sustainable 
development, societal utility and ethical considerations, according to the Norwegian Gene Technology 
Act and Regulations relating to impact assessment pursuant to the Gene Technology Act. These 
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considerations are therefore not part of the risk assessment provided by the VKM Panel on Genetically 
Modified Organisms.  
 
The genetically modified maize stack Bt11 x MIR604 x GA21 has been produced by conventional 
crossing between inbred lines of maize containing the single events Bt11, MIR604 and GA21. The F1 
hybrid was developed to provide protection against certain lepidopteran and coleopteran target pests, 
and to confer tolerance to glufosinate-ammonium glyphosate-based herbicides.  
 
Molecular characterisation  
Southern blot and PCR analyses have indicated that the recombinant inserts in the parental maize lines 
Bt11, MIR604 and GA21 are retained in the stacked maize Bt11 x MIR604 x GA21. Genetic stability 
of the inserts has previously been demonstrated in the parental maize lines. Protein levels measured by 
ELISA show comparable levels of the Cry1Ab, PAT, mCry3A, PMI and mEPSPS proteins between 
the stacked and single maize lines. Phenotypic analyses also indicate stability of the insect resistance 
and herbicide tolerance traits in the stacked maize. The VKM Panel on GMO considers the molecular 




Comparative analyses of data from field trials located at representative sites and environments in 
North America during the 2006 growing season indicate that maize stack Bt11 x MIR604 x GA21 is 
compositionally, agronomically and phenotypically equivalent to its conventional counterpart, with the 
exception of the insect resistance and the herbicide tolerance, conferred by the expression of Cry1Ab, 
mCry3A, PAT, PMI and mEPSPS proteins. 
 
Based on the assessment of available data, the VKM GMO Panel is of the opinion that conventional 
crossing of maize Bt11, MIR604 and GA21 to produce the hybrid Bt11 x MIR604 x GA21 does not 
result in interactions between the newly expressed proteins affecting composition and agronomic 
characteristics.   
 
Food and feed risk assessment 
A whole food feeding study on broilers has not indicated any adverse health effects of maize Bt11 x 
MIR604 x GA21, and shows that maize Bt11 x MIR604 x GA21 is nutritionally equivalent to 
conventional maize. The Cry1Ab, PAT, mEPSPS, mCry3A or PMI proteins do not show sequence 
resemblance to other known toxins or IgE allergens, nor have they been reported to cause IgE 
mediated allergic reactions. Some studies have however indicated a potential role of Cry-proteins as 
adjuvants in allergic reactions. 
 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 x MIR604 x GA21 is 
nutritionally equivalent to conventional maize varieties. It is unlikely that the Cry1Ab, PAT, mEPSPS, 
mCry3A or PMI proteins will introduce a toxic or allergenic potential in food or feed based on maize 
Bt11 x MIR604 x GA21 compared to conventional maize. 
 
Environmental risk assessment 
The scope of the application EFSA/GMO/UK/2008/56 includes import and processing of maize stack 
Bt11 x MIR604 x GA21 for food and feed uses. Considering the intended uses of maize Bt11 x 
MIR604 x GA21, excluding cultivation, the environmental risk assessment is concerned with 
accidental release into the environment of viable grains during transportation and processing, and 
indirect exposure, mainly through manure and faeces from animals fed grains from maize Bt11 x 
MIR604 x GA21.  
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Maize Bt11 x MIR604 x GA21 has no altered survival, multiplication or dissemination characteristics, 
and there are no indications of an increased likelihood of spread and establishment of feral maize 
plants in the case of accidental release into the environment of seeds from maize GA21. Maize is the 
only representative of the genus Zea in Europe, and there are no cross-compatible wild or weedy 
relatives outside cultivation. The VKM GMO Panel considers the risk of gene flow from occasional 
feral GM maize plants to conventional maize varieties to be negligible in Norway. Considering the 
intended use as food and feed, interactions with the biotic and abiotic environment are not considered 
by the GMO Panel to be an issue. 
 
Overall conclusion 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 x MIR604 x GA21 is 
nutritionally equivalent to conventional maize varieties. It is unlikely that the Cry1Ab, PAT, mEPSPS, 
mCry3A or PMI proteins will introduce a toxic or allergenic potential in food or feed based on maize 
Bt11 x MIR604 x GA21 compared to conventional maize. 
 
The VKM GMO Panel likewise concludes that maize Bt11 x MIR604 x GA21, based on current 
knowledge, is comparable to conventional maize varieties concerning environmental risk in Norway 
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I forbindelse med forberedelse til implementering av EU-forordning 1829/2003 i norsk rett har 
Miljødirektoratet (tidligere Direktoratet for Naturforvalting) bedt Mattilsynet om vurderinger av alle 
genmodifiserte organismer (GMOer) og avledete produkter som inneholder eller består av GMOer 
som er godkjent under forordning 1829/2003 eller direktiv 2001/18, og som er godkjent for ett eller 
flere bruksområder som omfattes av genteknologiloven. På den bakgrunnen har Mattilsynet, i brev av 
13. februar 2013 (ref. 2012/150202), bedt Vitenskapskomiteen for mattrygghet (VKM) om å utarbeide 
endelige vitenskapelige risikovurderinger av 39 GMOer og avledete produkter som inneholder eller 
består av genmodifiserte organismer, innen Mattilsynets sektoransvar. VKM er bedt om å ferdigstille  
endelige risikovurderinger for de EU-godkjente søknader hvor VKM ikke har avgitt endelig 
risikovurdering. I tillegg er VKM bedt om å vurdere hvorvidt det er nødvendig med oppdatering eller 
annen endring av de endelige risikovurderingene som VKM tidligere har levert. 
 
Den genmodifiserte maishybriden Bt11 x MIR604 x GA21 (Unik kode SYN-BTØ11-1 x SYN-IR6Ø4-
5 x MON-ØØØ21-9) fra Syngenta Seeds Inc. (søknad EFSA/GMO/UK/2008/56).  ) ble godkjent til 
import, videreforedling og bruk som mat og fôr under EU-forordning 1829/2003 22. desember 2011 
(Kommisjonsbeslutning 2011/893/EU). 
 
Maishybrid Bt11 x MIR604 x GA21 er tidligere vurdert av VKMs faggruppe for genmodifiserte 
organismer med hensyn på mulig helse- og miljørisiko i forbindelse med EFSAs offentlige høring av 
søknaden i 2008 (VKM 2008). Foreldrelinjene Bt11, MIR604 og GA21 er også tidligere risikovurdert 
av VKM, både som enkelt-eventer og i en rekke andre hybrider (VKM 2005a,b,c, 2007, 2009a,b,c,d, 
2010, 2011, 2012a,b). 
 
Risikovurderingen av den genmodifiserte maislinjen er basert på uavhengige vitenskapelige 
publikasjoner og dokumentasjon som er gjort tilgjengelig på EFSAs nettside EFSA GMO Extranet. 
Vurderingen er gjort i henhold til tiltenkt bruk i EU/EØS-området, og i overensstemmelse med 
miljøkravene i genteknologiloven med forskrifter, først og fremst forskrift om konsekvensutredning 
etter genteknologiloven. Videre er kravene i EU-forordning 1829/2003/EF, utsettingsdirektiv 
2001/18/EF (vedlegg 2,3 og 3B) og veiledende notat til Annex II (2002/623/EF), samt prinsippene i 
EFSAs retningslinjer for risikovurdering av genmodifiserte planter og avledete næringsmidler (EFSA 
2006, 2010, 2011a,b,c) lagt til grunn for vurderingen.  
 
Den vitenskapelige vurderingen omfatter transformeringsprosess og vektorkonstruksjon, 
karakterisering og nedarving av genkonstruksjonen, komparativ analyse av ernæringsmessig kvalitet, 
mineraler, kritiske toksiner, metabolitter, antinæringsstoffer, allergener og nye proteiner. Videre er 
agronomiske egenskaper, potensiale for utilsiktede effekter på fitness, genoverføring og effekter på 
ikke-målorganismer vurdert. 
 
Det presiseres at VKMs mandat ikke omfatter vurderinger av etikk, bærekraft og samfunnsnytte, i 
henhold til kravene i den norske genteknologiloven og dens konsekvensutredningsforskrift. Disse 
aspektene blir derfor ikke vurdert av VKMs faggruppe for genmodifiserte organismer. 
 
F1-hybriden Bt11 x MIR604 x GA21 er resultat av konvensjonelle kryssinger mellom innavlede 
maislinjer med eventene Bt11, MIR604 og GA21. Kryssingene er utført for å utvikle en maishybrid 
med resistens mot visse skadegjørere i sommerfuglordenen Lepidoptera og billeslekten Diabroticia, 
samt toleranse mot herbicider med virkestoff glufosinat-ammonium og glyfosat.  
 
Foreldrelinjen Bt11 inneholder de bakterielle genene cry1Ab og pat, fra henholdsvis Bacillius 
thuringiensis subsp. kurstaki og Streptomyces viridochromogenes strain Tu494. Cry1Ab-genet koder 
for et δ-endotoksin, som gir plantene toleranse mot enkelte arter i ordenen Lepidoptera. Pat-genet 
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koder for enzymet phosphinothricin acetyl transferase (PAT), som acetylerer og inaktiverer glufosinat-
ammonium, virkestoffet i fosfinotricin-herbicider av typen Finale. Fosfinotricin er et ikke-selektivt 
kontaktherbicid som hemmer glutaminsyntetase. Enzymet deltar i assimilasjonen av nitrogen og 
katalyserer omdanning av glutamat og ammonium til aminosyren glutamin. Hemming av 
glutaminsyntetase fører til akkumulasjon av ammoniakk, og til celledød i planten. Bt11-plantene vil 
derfor tolerere høyere doser av sprøytemiddelet glufosinat sammenlignet med konkurrerende ugras. 
 
Foreldrelinjen MIR604 har fått innsatt et modifisert cry3A-gen (mcry3A) fra Bacillius thuringiensis 
subsp. tenebrionis og genet pmi fra E. coli. mCry3A genet uttrykker δ-endotoksinet mCry3A, som gir 
plantene toleranse mot angrep fra bladbiller i slekten Diabrotica. Pmi genet uttrykker enzymet 
fosfomannose isomerase, som gir toleranse overfor sukkerarten mannose. 
 
Foreldrelinjen GA21 er fremkommet ved biolistisk transformasjon av embryonale maisceller fra en 
ikke navngitt maislinje. Den innsatte genkonstruksjonen inneholder et endogent 5-enolpyruvylsikimat-
3-fosfatsyntetase (mepsps)-gen, som er modifisert ved hjelp av in vitro-mutagenese. Mepsps-genet 
koder for enzymet 5-enolpyruvylsikimat-3-fosfatsyntetase (mEPSPS), som omdanner 
fosfoenolpyruvat og sikimat-3-fosfat til 5-enolpyruvylsikimat-3-fosfat, viktige metabolitter i syntesen 
av aromatiske aminosyrer. N-fosfonometylglycin er et systemisk, ikke selektivt herbicid som hemmer 
EPSPS-enzymer og blokkerer biosyntesen av aromatiske aminosyrer i planter. I motsetning til 
plantens EPSPS-enzym er det modifiserte mEPSPS-enzymet fra mais også aktivt ved nærvær av 
glyfosat. De transgene plantene vil derfor tolerere høyere doser av herbicider med virkestoff glyfosat 
sammenlignet med konkurrerende ugras. 
 
Molekylær karakterisering 
Maishybriden Bt11 x MIR604 x GA21 er dannet ved konvensjonelle kryssinger mellom maislinjene 
Bt11, MIR604 og GA21. Spaltingsdata, Southern blot og PCR-analyser indikerer at de rekombinante 
innskuddene fra mais Bt11, MIR604 og GA21 er stabilt nedarvet i mais Bt11 x MIR604 x GA21, og at 
antall innsatte gener, struktur og organiseringen av disse er ekvivalent med de som finnes i mais Bt11, 
MIR604 og GA21. Nivåene av Cry1Ab-, PAT-, mCry3A-, PMI- og mEPSPS-proteiner i vegetativt 
vev og korn fra mais Bt11 x GA21 er også sammenlignbare med nivåene i henholdsvis mais Bt11, 
MIR604 og GA21. 
 
Komparative analyser 
Data fra feltforsøk i Nord Amerika vekstsesongen 2006 indikerer, med unntak av insektsresistens og 
herbicidtoleranse, ekvivalens mellom maishybrid Bt11 x MIR604 x GA21 og korresponderende, nær-
isogen kontrollhybrid med hensyn på ernæringsmessige, agronomiske og fenotypiske karakterer.  
 
Basert på tilgjengelig dokumentasjon, konkluderer VKMs GMO-panel med at konvensjonelle 
kryssinger mellom de genmodifiserte maislinjene Bt11, MIR604 og GA21 ikke resulterer i nye 
interaksjoner mellom genproduktene fra de genmodifiserte foreldrelinjene som påvirker 
ernæringsmessige og agronomiske karakterer i hybriden Bt11 x MIR604 x GA21. 
 
Helserisiko 
I en fôringsstudie utført på broilere ble det vist at mais Bt11 x MIR604 x GA21 ikke førte til negative 
helseeffekter blant dyrene, og at maisen var ernæringsmessig ekvivalent konvensjonell mais. De 
introduserte proteinene Cry1Ab, PAT, mEPSPS, mCry3A og PMI viser ingen sekvenslikhet til kjente 
toksiner eller IgE-allergener. Det er heller ikke dokumentert at noen av disse proteinene kan utløse 
IgE-medierte allergiske reaksjoner. Enkelte studier har derimot indikert at noen typer Cry-proteiner 
potensielt kan forsterke andre allergiske reaksjoner (virke som adjuvans). 
 
Ut i fra dagens kunnskap konkluderer VKMs faggruppe for GMO at mais Bt11 x MIR604 x GA21 er 
ernæringsmessig ekvivalent med konvensjonell mais. Det er lite sannsynlig at proteinene Cry1Ab, 
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PAT, mEPSPS, mCry3A eller PMI vil introdusere et toksisk eller allergent potensiale i mat eller fôr 
basert på mais Bt11 x MIR604 x GA21 sammenliknet med konvensjonelle maissorter.  
 
Miljørisiko 
Søknaden EFSA/GMO/UK/2008/56 gjelder godkjenning av maislinje Bt11 x MIR604 x GA21 for 
import, prosessering og til bruk i næringsmidler og fôrvarer, og omfatter ikke dyrking. Med bakgrunn i 
tiltenkt bruksområde er miljørisikovurderingen avgrenset til mulige effekter av utilsiktet frøspredning i 
forbindelse med transport og prosessering, samt indirekte eksponering gjennom gjødsel fra husdyr 
fôret med genmodifisert mais.  
 
Det er ingen indikasjoner på økt sannsynlighet for spredning, etablering og invasjon av maislinjen i 
naturlige habitater eller andre arealer utenfor jordbruksområder som resultat av frøspill i forbindelse 
med transport og prosessering. Risiko for utkryssing med dyrkede sorter vurderes av GMO panelet til 
å være ubetydelig. Ved foreskreven bruk av maislinjen Bt11 x MIR604 x GA21 antas det ikke å være 
risiko for utilsiktede effekter på målorganismer, ikke-målorganismer eller på abiotisk miljø i Norge. 
 
Samlet vurdering  
Ut i fra dagens kunnskap konkluderer VKMs faggruppe for GMO at mais Bt11 x MIR604 x GA21 er 
ernæringsmessig ekvivalent konvensjonell mais. Det er lite sannsynlig at proteinene Cry1Ab, PAT,  
mCry3A, PMI eller mEPSPS vil introdusere et toksisk eller allergent potensiale i mat eller fôr basert 
på mais Bt11 x MIR604 x GA21 sammenliknet med konvensjonelle maissorter.  
 
Faggruppen finner at maishybrid Bt11 x MIR604 x GA21, ut fra dagens kunnskap og omsøkt bruk, er 
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Abbreviations and explanations 
 
ALS Acetolactate synthase, an enzyme that catalyses the first step in the 
synthesis of the branched-chain amino acids, valine, leucine, and 
isoleucine 
AMPA Aminomethylphosphonic acid, one of the primary degradation products of 
glyphosate 
ARMG Antibiotic resistance marker gene  
BC Backcross. Backcross breeding in maize is extensively used to move a 
single trait of interest (e.g. disease resistance gene) from a donor line into 
the genome of a preferred or “elite” line without losing any part of the 
preferred lines existing genome. The plant with the gene of interest is the 
donor parent, while the elite line is the recurrent parent. BC1, BC2 etc. 
designates the backcross generation number. 
BLAST Basic Local Alignment Search Tool. Software that is used to compare 
nucleotide (BLASTn) or protein (BLASTp) sequences to sequence 
databases and calculate the statistical significance of matches, or to find 
potential translations of an unknown nucleotide sequence (BLASTx). 
BLAST can be used to understand functional and evolutionary 
relationships between sequences and help identify members of gene 
families.  
bp Basepair 
Bt  Bacillus thuringiensis 
CaMV Cauliflower mosaic virus 
Codex Set by The Codex Alimentarius Commission (CAC), an intergovernmental 
body to implement the Joint FAO/WHO Food Standards Programme. Its 
principle objective is to protect the health of consumers and to facilitate 
the trade of food by setting international standards on foods (i.e. Codex 
Standards). 
Cry Any of several proteins that comprise the crystal found in spores of 
Bacillus thuringiensis. Activated by enzymes in the insects midgut, these 
proteins attack the cells lining the gut, and subsequently kill the insect. 
Cry1Ab Cry1 class crystal protein from Bacillus thuringiensis subsp. 
kurstaki.  Provide protection against certain lepidopteran target pests, such 
as the European maize borer (Ostrinia nubilalis), and species belonging to 
the genus Sesamia 
Cry3A Cry3 class crystal protein from Bacillus thuringiensis subsp. tenebrionis. 
Provide protection against certain coleopteran target pests. 
mCry3A Modified Cry3A protein optimized for maize 
CTP Chloroplast transit peptide 
DAP  Days after planting 
DNA Deoxyribonucleic acid 
DT50 Time to 50% dissipation of a protein in soil 
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DT90 Time to 90% dissipation of a protein in soil 
dw Dry weight 
dwt Dry weight tissue 
EC European Commission 
ECB European corn borer, Ostrinia nubilalis 
EFSA European Food Safety Authority 
ELISA Enzyme-linked immunosorbent assay 
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase 
ERA Environmental risk assessment 
E-score Expectation score 
EU European Union 
fa Fatty acid 
FAO Food and Agriculture Organisation 
FIFRA US EPA Federal Insecticide, Fungicide and Rodenticide Act 
Fitness Describes an individual's ability to reproduce successfully relative to that 
of other members of its population. 
fw Fresh weight 
fwt Fresh weight tissue 
GAT Glyphosate N-acetyltransferase 
GLP Good Laboratory Practice 
Glufosinate-ammonium Broad-spectrum  systemic herbicide 
Glyphosate Broad-spectrum  systemic herbicide 
GM Genetically Modified 
GMO Genetically Modified Organism 
GMP Genetically Modified Plant 
H Hybrid 
ha Hectare 
ILSI International Life Sciences Institute 
IPM Integrated Pest Management 
IRM Insect Resistance Management 
Locus The position/area that a given gene occupies on a chromosome 
LOD Limit of detection 
LOQ Limit of quantification 
MALDI-TOF Matrix-Assisted Laser Desorption/Ionization-Time Of Flight. A mass 
spectrometry method used for detection and characterisation of 
biomolecules, such as proteins, peptides, oligosaccharides and 
oligonucleotides, with molecular masses between 400 and 350,000 Da. 
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MCB Mediterranean corn borer, Sesamia nonagrioides 
mEPSPS Modified 5-enolpyruvylshikimate-3-phosphate synthase 
mRNA Messenger RNA 
MT Norwegian Food Safety Authority (Mattilsynet) 
NDF Neutral detergent fibre, measure of fibre used for animal feed analysis. 
NDF measures most of the structural components in plant cells (i.e. lignin, 
hemicellulose and cellulose), but not pectin. 
Northern blot Northern blot is a technique used to study gene expression by detection of 
RNA or mRNA separated in a gel according to size.  
NTO  Non-target organism 
Nicosulfuron Herbicide for maize that inhibits the activity of acetolactate synthase 
Near-isogenic lines  Term used in genetics/plant breeding, and defined genetic lines that are 
identical except for differences at a few specific locations or genetic loci. 
OECD Organisation for Economic Co-operation and Development 
ORF Open Reading Frame, in molecular genetics defined as a reading frame 
that can code for amino acids between two stop codons (without stop 
codons). 
OSL Over season leaf 
OSR Over season root 
OSWP Over season whole plant 
pat Phosphinothricin-Acetyl-Transferase gene 
PAT Phosphinothricin-Acetyl-Transferase protein 
PCR Polymerase chain reaction, a technique to amplify DNA by copying it 
PMI Phosphomannose Isomerase enzyme. Metabolizes mannose and allows 
positive selection for recovery of transformed plants. 
R0 First transformed generation, parent 
Rimsulferon Herbicide, inhibits acetolactate synthase 
RNA Ribonucleic acid 
RP Recurrent parent 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis. Technique 
to separate proteins according to their approximate size 
SAS Statistical Analysis System 
SD Standard deviation 
Southern blot Method used for transfer of electrophoresis-separated DNA fragments to a 
filter membrane and possible subsequent fragment detection by probe 
hybridisation 
T-DNA Transfer DNA, the transferred DNA of the tumour-inducing (Ti) plasmid 
of some species of bacteria such as Agrobacterium tumefaciens and A. 
rhizogenes, into plant's nuclear genome. The T-DNA is bordered by 25-
base-pair repeats on each end. Transfer is initiated at the left border and 
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terminated at the right border and requires the vir genes of the Ti plasmid. 
TI Trait integrated 
TMDI Theoretical Maximum Daily Intake 
U.S. EPA United States Environmental Protection Agency. 
Maize growth stages Vegetative 
 VE: emergence from soil surface 
 V1: collar of the first leaf is visible 
 V2: collar of the second leaf is visible  
 Vn: collar of the leaf number 'n' is visible  
 VT: last branch of the tassel is completely visible 
 Reproductive 
 R0: Anthesis or male flowering. Pollen shed begins 
 R1: Silks are visible 
 R2: Blister stage. The kernels are filled with a clear nourishing endosperm 
fluid and the embryo can be seen  
 R3: Milk stage. The kernels endosperm is milky white.  
 R4: Dough stage. The kernels endosperm has developed to a white paste  
 R5: Dent stage. If the genotype is a dent type, the grains are dented 
 R6: Physiological maturity 
 Western blot Technique used to transfer proteins separated by gel electrophoresis by 3-
D structure or denatured proteins by the length of the polypeptide to a 
membrane, where they might be identified by antibody labelling. 
WHO World Health Organisation 
ZM Zea maize L. 
ZM-HRA A modified version of the native acetolactate synthase protein from maize. 
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On 28 May 2008, the European Food Safety Authority (EFSA) received from the Competent 
Authority of the United Kingdom an application (Reference EFSA/GMO/UK/2008/56) for 
authorisation of the insect-resistant and herbicide-tolerant genetically modified (GM) maize Bt11 x 
MIR604 x GA21 (Unique Identifier SYNBTØ11-1xSYN-IR6Ø4-5xMON-ØØØ21-9), submitted by 
Syngenta Seeds S.A.S. within the framework of Regulation (EC) No 1829/2003.  
 
The scope of the application covers:  
• Import and processing of maize Bt11 x MIR604 x GA21 
• GM plants for food and feed use 
• Food and feed, containing or consisting of maize Bt11 x MIR604 x GA21 
• Food and feed produced from maize Bt11 x MIR604 x GA21  
• Food containing ingredients produced from maize Bt11 x MIR604 x GA21 
 
After receiving the application EFSA/GMO/UK/2008/56 and in accordance with Articles 5(2)(b) and 
17(2)b of Regulation (EC) No 1829/2003, EFSA informed the EU- and EFTA Member States (MS) 
and the European Commission and made the summary of the dossier publicity available on the EFSA 
website. EFSA initiated a formal review of the application to check compliance with the requirements 
laid down in Articles 5(3) and 17(3) of regulation (EC) No 1829/2003. On 24 July 2008, EFSA 
declared the application as valid in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 
1829/2003.  
 
EFSA made the valid application available to Member States and the EC and consulted nominated risk 
assessment bodies of the MS, including the Competent Authorities within the meaning of Directive 
2001/18/EC (EC 2001), following the requirements of Articles 6(4) and 18(4) of Regulation (EC) No 
1929/2003, to request their scientific opinion. Within three months following the date of validity, all 
MS could submit via the EFSA GMO Extranet to EFSA comments or questions on the valid 
application under assessment.  
 
The EFSA GMO Panel its scientific opinion in May 2010 (EFSA 2010b). The Commission Decision 
2011/893/EC authorised the placing on the market of products containing, consisting of, or produced 
from maize Bt11 x MIR604 x GA21 pursuant to Regulation (EC) No 1829/2003 (EC 2008) on 22 
December 2011.  
 
An application for authorisation of seeds and plant propagation materials for cultivation of maize Bt11 
x MIR604 x GA21 in the EU was submitted by Syngenta Seeds in July 2010 
(EFSA/GMO/UK/2010/84). EFSA stopped the application process in October 2011, pending the 
finalisation of the risk assessment of the applications EFSA/GMO/UK/2008/60 (maize GA21) and 
EFSA/GMO/UK/2010/83 (maize MIR604). The EFSA GMO Panel adopted its scientific opinion on 
maize GA21 in December 2011 (EFSA 2011d). EFSA has however requested additional information 
from Syngenta regarding maize MIR604 and the clock for application EFSA/GMO/UK/2010/84 
remains stopped by EFSA. 
 
Genetically modified maize Bt11 x MIR604 x GA21 has previously been risk assessed by the VKM 
Panel on Genetically Modified Organisms (GMO), commissioned by the Norwegian Food Safety 
Authority  and the Norwegian Environment Agency related to the EFSAs public hearing of the 
application EFSA/GMO/UK/2008/56 in 2008 (VKM 2008a). In addition, Bt11, MIR604 and GA21 
has been evaluated by the VKM GMO Panel as single events and as a component of several stacked 
GM maize events (VKM 2005a,b,c, 2007, 2009a,b,c,d, 2010, 2011, 2012a,b,). 
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Exemption of the authorisation requirements of 19 existing products in Norway 
Through the Agreement of the European Economic Area (EEA), Norway is obliged to implement the 
EU regulations on GM food and feed (regulations 1829/2003, 1830/2003 et al). Until implementation 
of these regulations, Norway has a national legislation concerning processed GM food and feed 
products that are harmonised with the EU legislation. These national regulations entered into force 15 
September 2005. For genetically modified feed and some categories of genetically modified food, no 
requirements of authorisation were required before this date. Such products that were lawfully placed 
on the Norwegian marked before the GM regulations entered into force, the so-called existing 
products, could be sold in a transitional period of three years when specific notifications were sent to 
the Norwegian Food Safety Authority. Within three years after 15. September 2005, applications for 
authorisation should be sent to the Authority before further marketing. Four fish feed producing 
companies have once a year since 2008, applied for an exemption of the authorisation requirements of 
19 existing products, including maize Bt11 and GA21. These 19 GM events are all authorised in the 
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Terms of reference 
 
The Norwegian Environment Agency has the overall responsibility for processing applications for the 
deliberate release of genetically modified organisms (GMOs). This entails inter alia coordinating the 
approval process, and to make a holistic assessment and recommendation to the Ministry of the 
Environment regarding the final authorization process in Norway. The Directorate is responsible for 
assessing environmental risks on the deliberate release of GMOs, and to assess the product's impact on 
sustainability, benefit to society and ethics under the Gene Technology Act. 
 
The Norwegian Food Safety Authority (NFSA) is responsible for assessing risks to human and animal 
health on deliberate release of GMOs pursuant to the Gene Technology Act and the Food Safety Act. 
In addition, the NFSA administers the legislation for processed products derived from GMO and the 
impact assessment on Norwegian agriculture according to sector legislation. 
 
In preparation for a legal implementation of EU-regulation 1829/2003, the Norwegian Environment 
Agency has requested the Norwegian Food Safety Authority to give final opinions on all genetically 
modified organisms (GMOs) and products containing or consisting of GMOs that are authorized in the 
European Union under Directive 2001/18/EC or Regulation 1829/2003/EC within the Authority’s 
sectoral responsibility.  The request covers scope(s) relevant to the Gene Technology Act.  
  
The Norwegian Food Safety Authority has therefore, by letter dated 13 February 2013 (ref. 
2012/150202), requested the Norwegian Scientific Committee for Food Safety (VKM) to carry out 
final scientific risk assessments of 39 GMOs and products containing or consisting of GMOs that are 
authorized in the European Union.  
  
The assignment from NFSA includes food and feed safety assessments of genetically modified 
organisms and their derivatives, including processed non-germinating products, intended for use as or 
in food or feed.  
  
In the case of submissions regarding genetically modified plants (GMPs) that are relevant for 
cultivation in Norway, VKM is also requested to evaluate the potential risks of GMPs to the 
Norwegian agriculture and/or environment. Depending on the intended use of the GMP(s), the 
environmental risk assessment should be related to import, transport, refinement, processing and 
cultivation. If the submission seeks to approve the GMP(s) for cultivation, VKM is requested to 
evaluate the potential environmental risks of implementing the plant(s) in Norwegian agriculture 
compared to existing varieties (e.g. consequences of new genetic traits, altered use of pesticides and 
tillage). The assignment covers both direct and secondary effects of altered cultivating practices.  
  
VKM is further requested to assess risks concerning coexistence of cultivars. The assessment should 
cover potential gene flow from the GMP(s) to conventional and organic crops as well as to compatible 
wild relatives in semi-natural or natural habitats. The potential for establishment of volunteer 
populations within the agricultural production systems should also be considered. VKM is also 
requested to evaluate relevant segregation measures to secure coexistence during agricultural 
operations up to harvesting. Post-harvest operations, transport, storage are not included in the 
assignment.  
  
Evaluations of suggested measures for post-market environmental monitoring provided by the 
applicant, case-specific monitoring and general surveillance, are not covered by the assignment from 
the Norwegian Food Safety Authority. 
 
 










The genetically modified maize stack Bt11 x MIR604 x GA21 has been produced by conventional 
crossing between inbred lines of maize containing the single events Bt11, MIR604 and GA21. The F1 
hybrid was developed to provide protection against certain lepidopteran and coleopteran target pests, 
and to confer tolerance to glufosinate-ammonium and glyphosate-based herbicides.  
 
None of the target pests for maize Bt11 x MIR604 x GA21 are present in the Norwegian agriculture. 
The PAT protein expressed in maize Bt11 has been used as selectable markers to facilitate the 
selection process of transformed plant cells and is not intended for weed management purposes. 
 
Maize stack Bt11 x MIR604 x GA21 has been evaluated with reference to its intended uses in the 
European Economic Area (EEA), and according to the principles described in the Norwegian Food 
Act, the Norwegian Gene Technology Act and regulations relating to impact assessment pursuant to 
the Gene Technology Act, Directive 2001/18/EC on the deliberate release into the environment of 
genetically modified organisms, and Regulation (EC) No 1829/2003 on genetically modified food and 
feed.  
 
The Norwegian Scientific Committee for Food Safety has also decided to take into account the 
appropriate principles described in the EFSA guidelines for the risk assessment of GM plants and 
derived food and feed (EFSA 2011a), the environmental risk assessment of GM plants (EFSA 2010), 
the selection of comparators for the risk assessment of GM plants (EFSA 2011b), and for the post-
market environmental monitoring of GM plants (EFSA 2011c).  
 
The food/feed and environmental risk assessment of the genetically modified maize Bt11 x MIR604 x 
GA21 is based on information provided by the applicant in the applications EFSA/GMO/UK/2005/20, 
and scientific opinions and comments from EFSA and other member states made available on the 
EFSA website GMO Extranet. The risk assessment is also based on a review and assessment of 
relevant peer-reviewed scientific literature.  
 
It is emphasized that the VKM mandate does not include assessments of contribution to sustainable 
development, societal utility and ethical considerations, according to the Norwegian Gene Technology 
Act and Regulations relating to impact assessment pursuant to the Gene Technology Act. These 
considerations are therefore not part of the risk assessment provided by the VKM Panel on Genetically 
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2 Molecular characterisation 
 
2.1 Evaluation of relevant scientific data 
 
2.1.1 Method of production of maize Bt11 x MIR604 x GA21 
 
The Bt11 x MIR604 x GA21 maize has been produced by crossing genetically modified insect- 
resistant Bt11 and MIR604 maize and herbicide tolerant GA21 maize through conventional breeding 
techniques.  
 
Bt11 x MIR604 x GA21 maize plants contain the five traits present in Bt11, MIR604 and GA21 maize 
plants through the production of: 
  
1. A truncated Cry1Ab protein for control of certain lepidopteran pests like the common European 
maize pests: Ostrinia nubilalis (European corn borer; ECB) and Sesamia nonagrioides (Mediterranean 
corn borer; MCB). 
 
2. A phosphinothricin acetyltransferase (PAT) protein that confers tolerance to herbicide products 
containing glufosinate ammonium. 
 
3. A modified Cry3A (mCry3A) protein for control of certain coleopteran pests like Diabrotica 
virgifera virgifera (Western corn rootworm; WCRW) a maize pest recently introduced and rapidly 
expanding in the EU. 
 
4. A phosphomannose isomerase (MIR604 PMI) protein as a selectable marker. PMI allows 
transformed corn cells to grow on a minimal medium during tissue culture, while non-transformed 
cells fail to and thereby are selected against (removed). GM cells utilize mannose as a sole carbon 
source, and this selection replaces previously controversial commonly used antibiotic resistance and as 
such meets demands to avoid using antibiotics.  
 
5. A modified maize 5-enolpyruvylshikimate-3-phosphate synthase enzyme (mEPSPS) that confers 
tolerance to herbicide products containing glyphosate. 
 
 
2.1.2 Summary of evaluation of the single events 
 
2.1.2.1 Maize Bt11 
 
Maize Bt11 was generated by transformation of a proprietary inbred maize line, H8540, using a DNA 
fragment obtained by a restriction digest of the plasmid pZO1502 with the enzyme NotI by biolistics. 
Regenerated plants were backcrossed to a selected line resulting in maize Bt11. The DNA fragment 
used for transformation carried two expression cassettes; a selectable marker gene pat, encoding 
phosphinothricin-N-acetyl transferase and a trait gene encoding a variant Bacillus thuringiensis 
cry1Ab gene encoding Bt endotoxin. Both the cry1Ab and pat gene cassette are controlled by the 35S 
promoter from the Cauliflower mosaic virus (CaMV), supplemented with the intron sequences to 
enhance gene expression. The polyadenylation signals are derived from the nopaline synthase (nos) 
gene from Agrobacterium tumefaciens (Fig.1).  
 
Southern analyses of the single maize event Bt11 used a variety of DNA probes that included the pat 
and cry1Ab genes as probes for the genes intended to be inserted and the amp gene and the entire 
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plasmid as probes to detect genome wide unintended insertions. The data obtained indicated that 
maize Bt11 contains a single DNA insertion with one copy of both the cry1Ab and the pat cassettes.  
 
The entire Bt11 maize insert including the flanking regions was sequenced. The maize sequences 
flanking the Bt11 maize insert were also identified. A BLAST analysis of the sequences flanking the 
Bt11 maize insert was carried out against publicly available nucleotide databases. DNA sequences at 
the junctions between the insert and the parent genome were determined. At the 5’ flank, 
approximately 350 bp of the plant DNA adjacent to the insert was sequenced. At the 3’ flank, 
approximately 540 bp of the plant DNA adjacent to the insert was sequenced. The 5’ and 3’ flanking 
sequences were screened for homologies with sequences found in public databases. BLAST analysis 
of both the 5’ and 3’ regions of the Bt11 maize insert revealed homology primarily to the Zea mays 
180 bp knob-associated tandem repeat. The data do not indicate any safety concern with regard to the 
interruption of known genes or from the potential production of new toxins or allergens.  
 
The range of expression of Cry1Ab and PAT proteins in Bt11 maize plants were determined by 
ELISA in several plant tissues and whole plants at various growth stages from different hybrids.  
 
Levels in pollen were below the lower limit of quantification, < 0.08 µg/g fresh wt. pollen and < 0.15 
µg/g dry wt. pollen. Across all plant stages, mean Cry1Ab levels measured in leaves, roots and whole 
plants ranged from ca. 10 - 22 µg/g fresh wt. (12 – 154 µg/g dry wt.), 2 – 4 µg/g fresh wt. (9 – 22 µg/g 
dry wt.), and 4 – 9 µg/g fresh wt. (6 – 70 µg/g dry wt.), respectively. Mean Cry1Ab levels measured in 
grain at seed maturity and senescence were 1 – 2 µg/g fresh wt (2 µg/g dry wt.).  
 
The level of the Cry1Ab protein was present at low levels in Bt11 sweet maize hybrids. Cry1Ab 
protein was not detectable in any of the canned maize samples tested. The level of the PAT protein 
was determined using Bt11 field maize plants; measurable levels (ng/g) were only found in leaves, silk 
and tassel. For grain, pollen, root and stalk concentrations were below the limits of detection. The PAT 
protein is present at less than 0.000008% fresh weight and 0.00016% of the total maize grain protein. 
 
The genetic stability of the inserted DNA in maize Bt11 was demonstrated over several generations by 
Southern analysis. Segregation data for PAT and Cry1Ab (glufosinate-ammonium tolerance and insect 
resistance) also demonstrated the traits are stable and inherited according to Mendelian segregation of 
a single genetic locus. 
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2.1.2.2. Maize MIR604 
 
Maize MIR604 was developed by transforming immature maize embryos derived from a proprietary 
Zea mays line (A188) via Agrobacterium-mediated transformation, using the binary transformation 
vector pZM26. The T-DNA genetic elements transferred to produce maize MIR604 are shown in 
Figure 2.  
Maize MIR604 expresses the mcry3A gene, which is a modified version of the cry3A gene from 
Bacillus thuringiensis subsp. tenebrionis. The mcry3A gene encodes the mCry3A protein that confers 
resistance to the Western Corn rootworm (Diabrotica virgifera virgifera) and other related coleopteran 
pests of maize. The native cry3A gene was modified to incorporate a cathepsin-G serine protease 
recognition site within the expressed protein. The original N-terminal region of this protein has been 
removed and the mCry3A protein commences at a methionine residue in position 48 of the native 
protein. The mcry3A gene is regulated by the promoter from the metallothionein-like gene from Zea 
mays, which is preferentially expressed in root tissue, and the nopaline synthase (NOS) terminator 
from Agrobacterium tumefaciens. 
 
MIR604 also expresses the pmi (manA) gene from Escherichia coli, which encodes the enzyme 
phosphomannose isomerase (PMI). The gene was introduced as a selectable marker for the 
development of maize MIR604. Mannose is taken up by plants and converted to mannose-6-phosphate 
by hexokinase. Usually this product cannot be further utilised in maize plants as they lack the PMI 
enzyme. The accumulation of mannose-6-phosphate inhibits phosphoglucose isomerase, causing a 
block in glycolysis. It also depletes cells of orthophosphate required for the production of ATP. 
Therefore, while mannose has no direct toxicity on plant cells, it causes growth inhibition. This does 
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not occur in plants transformed with the pmi gene as they can utilise mannose as a source of carbon. 
The pmi gene is regulated by the polyubiquitin promoter (ZmUbilnt) from Zea mays and the NOS 
terminator from A. tumefaciens.  
 
 
Figure 2. Genes and regulatory elements inserted in MIR604 
 
Southern blot analyses have indicated that the maize event MIR604 contains a single intact T-DNA 
from plasmid pZM26, without the plasmid backbone. 
Sequence analyses of the T-DNA including the flanking regions have shown that a 8416 bp T-DNA 
was inserted in the maize genome, and that a 44bp segment was missing from the Right border region, 
and 43bp at the Left border region. Three base pair changes were found within the insert in MIR604: 
one within the MTL promoter, and two within the pmi gene. These modifications have resulted in two 
amino acid substitutions, however without affecting the functions of the inserted elements in MIR604. 
The sequence analyses indicated that the overall integrity of the insert and the contiguousness of the 
functional elements from pZM26 are maintained.  
 
BLAST analyses show that the insertion of the T-DNA in MIR604 occurred in a region of the Zea 
mays genome that was not well annotated and that the insert further did not appear to disrupt any 
identified endogenous Zea mays genes. Analyses of the six potential reading frames covering the T-
DNA and genome junctions, did not show the presence of any novel ORF. 
 
The levels of mCry3A and PMI proteins in maize MIR604 were determined by ELISA at the four 
growth stages: whorl, anthesis, seed maturity and senescence.  
Across all growth stages, mean mCry3A levels measured ranged from 4 – 94 µg/g dry weight (dw) in 
leaves, 7 – 62 µg/g dw in roots, and 3 - 28 µg/g dw in whole plants. Mean mCry3A levels measured in 
grain at seed maturity and senescence ranged from 0.8 – 2.0 µg/g dw. Mean mCry3A levels measured 
in silk tissue at anthesis were below the lower limit of quantification (LOQ), <1.0 µg/g dw.  Mean 
mCry3A levels measured in silk tissue at seed maturity ranged from 1 – 3 µg/g dw.  No mCry3A 
protein was detectable in pollen.   
PMI protein was detected in most maize MIR604 plant tissues, although at low levels. Across all plant 
stages, mean PMI levels ranged from not detectable (ND) to 2.1 µg/g dw in leaves, below the LOQ  
(<0.04 µg/g dw) to 2 µg/g dw in roots, and below the LOQ (<0.1 µg/g dw) to 1.0 µg/g dw in whole 
plants. Mean PMI levels measured in grain at seed maturity and senescence ranged from below the 
LOQ (<0.07 µg/g dw) to 0.5 µg/g dw.  Mean PMI levels measured in silk tissue at anthesis and seed 
maturity ranged from below the LOQ (<0.2 µg/g dw.) to 6.8 µg/g dw.  PMI in pollen ranged from 3.9 
– 5.2 µg/g dw.  
 
Overall levels of mCry3a protein were similar across four generations analysed without any significant 
trend either up or down, indicating that the expression of mcry3A in MIR604 is stable. A similar result 
was obtained for the PMI protein. Since no novel ORF were identified that spanned either the 5’ or 3’ 
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junctions between the MIR604 T-DNA and Zea mays genomic sequence, no fusion protein is 
expected. 
Segregation analyses of both trait negative and trait positive plants, determined by ELISA and PCR, 
from a selected generation of maize (T5), have shown that the introduced traits in MIR604 are stably 
inherited in a Mendelian fashion, by Chi square analysis.  
 
 
2.1.2.3. Maize GA21 
 
Maize GA21 was generated by microprojectile bombardment transformation with a 3.49 kb NotI 
restriction fragment of the plasmid pDPG434 (derived from pUC19 via cloning into a commonly used 
pSK-vector). The DNA fragment used for transformation consisted of the following mepsps cassette: 
the rice actin promoter (5’ region of the rice actin 1 gene containing the promoter and first non-coding 
exon and intron), an optimised transit peptide containing sequences from maize and sunflower, a 
modified maize epsps coding sequence (mepsps), and the 3‟ nos terminator from Agrobacterium 
tumefaciens. The mutations in the coding sequence of the maize epsps gene led to amino acid changes 
at positions 102 (threonine to isoleucine) and 106 (proline to serine). As a result of these mutations, 
the mepsps containing maize line GA21 is tolerant to glyphosate-based herbicides. The vector 
backbone contained the origin of replication (ori ColE1), the lac sequence as present in pUC19, and 
the bacterial bla gene conferring resistance to ampicillin in bacteria (Fig. 3). The mEPSPS is only 
different from the naturally present EPSPS protein by two amino acids.  
 
Southern analyses showed that the insert in maize GA21 consists of six contiguous complete and 
truncated versions (fragments 1 to 6) of the 3.49 kb NotI restriction fragment. The insertions are 
located as a single locus. The absence of vector backbone sequences in GA21 plants has been 
demonstrated using a probe specific for the pDPG434 vector backbone. Therefore, the bla gene has 
not been transferred to maize GA21.  
 
The nucleotide sequence of the insert introduced into maize GA21 has been determined in its entirety 
and even though regarded as a single locus consisting of six fragments or copies of the transgene 
construct as specified below. Fragment 1 contains the rice actin promoter with a deletion of 696 bp at 
the 5’ end, the actin first exon and intron, the optimized transit peptide, the mepsps gene and nos 
terminator. Fragments 2, 3 and 4 are complete versions of the 3.49 kb NotI fragment. Fragment 5 
contains the complete rice actin promoter, the actin first exon and intron, the optimized transit peptide, 
and 288 bp of the mepsps gene which ends in a stop codon. Fragment 6 only contains the rice actin 
promoter and a truncated actin first exon. A single base pair change was observed in the nos 
terminator in fragments 1 and 2 (nucleotide C instead of G). In addition, a single base pair deletion is 
observed in the actin promoter of fragment 6. The observed mutations do not have any impact on the 
amino acid sequence of the newly expressed protein.  
 
The sequences of 1 kb of the plant genome adjacent to the 3’ and 4.2 kb at the 5’ end were also 
determined and bioinformatic analysis gave no indication that the sequence was inserted in a 
functional maize gene. The 3‟ sequence shows homology to repetitive sequences in the maize genome. 
The 5‟ flanking sequence was shown to be of chloroplast origin. The five putative ORFs found at the 
junction between the insert and the plant DNA show no significant sequence homology to any known 
toxic proteins or allergens. One potential new ORF was apparently created at the junction between 
fragment 5 and 6 but lacked the necessary components to be likely to be transcribed. This ORF does 
not show homology to known or putative allergens or toxic proteins. Updated (2008) bioinformatic 
analysis of the 5‟ and 3‟ flanking regions of the GA21 insert provided data which were similar to that 
previously reported and do not indicate any safety concerns with regard to the interruption of known 
genes or from the potential production of new toxins or allergens.  
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The concentrations of the mEPSPS protein in maize plants derived from GA21 were examined by 
ELISA in several plant tissues and whole plants at four growth stages (whorl, anthesis, seed maturity 
and senescence) in two maize hybrids. Across all growth stages, mean mEPSPS concentrations 
measured in leaves, roots and whole plants ranged from below the limit of quantification (<0.2 µg/g 
fw) to 15 µg/gfw (<0.4—71 µg/g dw). Mean mEPSPS concentrations measured in grain ranged from 
4—7 µg/g fw (5—10 µg/gdw) and in pollen averaged 168 µg/g fw.  
 
The inheritance of the introduced glyphosate tolerant phenotype follows a Mendelian segregation 
pattern of a single functional locus and the mEPSPS protein is stably expressed in maize GA21 across 
multiple generations. Southern analysis demonstrated that the insert in maize GA21 is stably inherited 
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2.1.3 Transgene constructs in Bt11 x MIR604 x GA21 maize 
 
The integrity of the individual inserts present in Bt11 x MIR604 x GA21 maize was investigated using 
Southern analyses. This involved the use of DNA probes specific for the Bt11, MIR604 and GA21 
inserts and enzymatic digestions informative of the structure of the three events, including the 
junctions with the host genomic DNA. According to the applicant, the predicted DNA hybridisation 




2.1.3.1 Information on the expression of insert 
 
The levels of newly expressed proteins Cry1Ab, PAT, mCry3A, PMI and mEPSPS in forage and grain 
of maize Bt11 x MIR604 x GA21 were assessed by enzyme-linked immunosorbent assay (ELISA). 
According to the applicant, the plants used in this study were grown in 2006 at a Syngenta Seeds 
research station in USA, according to standard local agronomic practices. A set of four maize plants 
were collected at anthesis (stage) from each of five replicate blocks and a set of two plants were 
collected at maturity (physiological stage), also from five replicate blocks. From these plants, leaves, 
roots, and whole plants at the same stages were analyzed to compare the concentrations of transgenic 
proteins in the hybrids listed above. Five replicated pollen samples per hybrid were collected in the 
field, and analyzed by ELISA in the same manner. 
 
The scope of the application covers food and feed uses, import and processing, therefore protein 
expression data related to the grains is considered the most relevant. These data are summarised in 
Table 1. The results indicate that for Cry1Ab and PAT, the overall concentrations were generally 
comparable between the Bt11 x MIR604 x GA21 hybrid and the Bt11 hybrid. For mCry3A and 
MIR604 PMI, the overall concentrations were, generally comparable between the Bt11 x MIR604 x 
GA21 hybrid and the MIR604 hybrid. Similarly, the overall concentrations of mEPSPS were 
comparable between the Bt11 x MIR604 x GA21 hybrid and the GA21 hybrid (data not shown).  
 
Cry1Ab, PAT, mCry3A, MIR604 PMI and mEPSPS concentrations in the near-isogenic, non-
transgenic control samples were below the limit of detection. Some statistically significant differences 
were seen, but these differences were small or not consistent across the growing season.  
 
2.1.3.2  Parts of the plant where the insert is expressed 
To characterize the range of expression of Cry1Ab, PAT, mCry3A, MIR604 PMI and mEPSPS 
proteins in Bt11 x MIR604 x GA21 maize plants, the concentrations of these proteins were determined 
by ELISA in several plant tissues (leaves, roots, grain and pollen).  
 
According to the applicant, the concentrations of Cry1Ab, PAT, mCry3A, MIR604 PMI, and mEPSPS 
proteins were generally similar between the stacked Bt11 × MIR604 × GA21 maize hybrid and the 
corresponding single-events Bt11, MIR604, and GA21. Out of 20 statistical comparisons of all the 
transgenic protein concentrations between the single event hybrids and the stacked hybrid, only two 
significant differences (significant difference established as an F-Test value less than the customary 
5% level) were observed. The two significant differences observed were in root tissue, for which the 
Cry1Ab protein concentrations in the Bt11 hybrid and the mEPSPS protein concentrations in the 
GA21 hybrid were higher than those of the Bt11 × MIR604 × GA21 hybrid. Although the measured 
concentrations of these two proteins in Bt11 × MIR604 × GA21 hybrid root tissue were lower than the 
concentrations measured in root tissue of the two single-event hybrids, the ranges of all protein 
concentrations from individual replicate samples of the single-event hybrids overlapped considerably 
with those of the stacked hybrid. Furthermore, the concentrations of both mEPSPS and Cry1Ab 
proteins in whole-plant samples of the Bt11 × MIR604 × GA21 hybrid were not significantly different 
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from those of the two single-event hybrids. The VKM GMO panel  do not believe this difference pose a 
safety concern and that the difference is not there at the whole plant level which is more relevant for farming 
practice and the harvested plant parts. 
 
Quantifiable concentrations of Cry1Ab protein were detected in leaves, roots and grains derived from 
Bt11 and Bt11 x MIR604 x GA21 maize. Very low levels of Cry1Ab expression were detected in  
pollen for both hybrids. 
 
Quantifiable concentrations of PAT protein were detected in leaves and roots derived from Bt11 and 
Bt11 x MIR604 x GA21 maize at most stages of development, however no quantifiable levels could 
be detected in grains or pollen.  
 
Quantifiable concentrations of mCry3A protein were detected in leaves, roots and grains derived from 
MIR604 and Bt11 x MIR604 x GA21 maize. Very low levels of mCry3A expression were detected in 
the pollen of MIR604 and Bt11 x MIR604 x GA21.  
 
Quantifiable concentrations of MIR604PMI and mEPSPS protein were detected in all MIR604 and 
Bt11 x MIR604 x GA21 maize plant tissues analysed.  
 
 
2.1.3.3  Potential fusion proteins 
 
Bt11 x MIR604 x GA21 maize was produced by combining Bt11, MIR604 and GA21 maize 
through conventional breeding. An Open Reading Frame (ORF) analysis was performed for 
each of the single events. 
 
2.1.3.4  Inheritance and genetic stability of inserted DNA 
 
Molecular analyses indicate that the insert has been stably integrated into the plant genome in 





Southern blot and PCR analyses have indicated that the recombinant inserts in the parental maize lines 
Bt11, MIR604 and GA21 are retained in the stacked maize Bt11 x MIR604 x GA21. Genetic stability 
of the inserts has previously been demonstrated in the parental maize lines. Protein levels measured by 
ELISA show comparable levels of the Cry1Ab, PAT, mCry3A, PMI and mEPSPS proteins between 
the stacked and single maize lines. Phenotypic analyses also indicate stability of the insect resistance 
and herbicide tolerance traits in the stacked maize. The VKM Panel on GMO considers the molecular 
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3 Comparative assessment 
 
3.1 Choice of comparator and production of material for the 
compositional assessment 
 
3.1.1  Summary of the previous evaluation of the single events 
 
3.1.1.1 Maize Bt11  
Maize Bt11 was compared to non-transgenic maize with a comparable genetic background. Forage 
and grain samples were collected for compositional analysis from field trials conducted in USA 
(studies involving 3-6 sites in 1995) and Europe (two locations in 1998). No consistent compositional 
differences were observed between maize Bt11 and non-transgenic maize. In addition, field trials over 
several seasons at different locations in Europe did not indicate significant differences between maize 
Bt11 and its comparators with respect to agronomical and phenotypical characteristics, except for 
herbicide tolerance and insect resistance.  
 
Maize Bt11 has a long history of use and has been evaluated extensively by The VKM GMO Panel. In 
the latest risk assessment, it was concluded that maize Bt11 is compositionally, agronomically and 
phenotypically equivalent to conventional maize varieties, except for the herbicide tolerance and 
insect resistance traits conferred by the transgenic proteins Cry1Ab and PAT (VKM 2014a).  
 
3.1.1.2  Maize MIR604 
Maize MIR604 was compared to non-transgenic maize with comparable genetic background (near-
isogenic control) during field trials at multiple locations in USA in 2002 and 2003. The composition of 
forage and grain samples were analysed in line with recommendations from the OECD consensus 
document on key nutrients, anti-nutrients, and secondary plant metabolites of maize (OECD 2002). No 
consistent compositional differences were observed between maize MIR604 and non-transgenic 
maize.  Agronomic traits were assessed during field trials (and greenhouse trials) at 22 locations in 8 
states in USA in 2002 and 2003. The results did not indicate consistent differences between maize 
MIR604 and its comparators with respect to agronomical and phenotypical characteristics, except for 
insect resistance.  
 
Analyses of mono- and disaccharides, including phosphorylated forms of these saccharides, in maize 
MIR604 and near-isogenic control, were performed by the applicant at six locations in USA in 2006 at 
the request of the EFSA GMO Panel. In compounds that could theoretically be linked to PMI activity 
(e.g., starch and other carbohydrates), no consistent compositional differences were observed in the 
comparison between maize MIR604 and control.  
 
In the latest risk assessment of maize MIR604 the VKM GMO Panel concludes that maize MIR604 is 
compositionally, agronomically and phenotypically equivalent to conventional maize varieties, except 
for the presence of the transgenic proteins and the insect resistance traits conferred by the mCry3A 
protein (VKM 2014b).  
 
3.1.1.3 Maize GA21  
Maize GA21 was compared to non-transgenic maize with a comparable genetic background (near-
isogenic control) during field trials at multiple locations and over several seasons: five locations in 
USA in 1996, seven locations in USA in 1997, four locations in Europe in 1997 and six locations 
during two seasons in USA in 2004 and 2005. Maize GA21 plants treated with glyphosate-based 
herbicides as well as plants untreated with the target herbicides were included in these field trials. No 
consistent compositional differences were observed between maize GA21 and non-transgenic maize. 
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Agronomic traits were assessed during multiple field trials and seasons in USA in 2004, Brazil in 2003 
and Europe in 2007 and 2008. Results from these field trials did not indicate consistent differences 
between maize GA21 and its comparators with respect to agronomical and phenotypical 
characteristics, except herbicide tolerance.  
 
In the latest risk assessment of maize GA21 the VKM GMO Panel concludes that maize GA21 is 
compositionally, agronomically and phenotypically equivalent to conventional maize varieties, except 
for the herbicide tolerance conferred by the mEPSPS protein (VKM 2014c).  
 
3.1.2 Experimental design & statistical analysis 
 
Bt11 x MIR604 x GA21 maize was produced by combining Bt11, MIR604 and GA21 maize through 
conventional breeding techniques. All three single GM maize events have previously been compared 
to their respective near-isogenic conventional maize lines for their nutritional effects on humans and 
animal health. Data on comparisons of agronomic characteristics and compositional analysis between 
Bt11 maize and near-isogenic non-GM conventional maize, MIR604 maize and near-isogenic maize 
as well as GA21 maize and near-isogenic maize were generated from field trials conducted at several 
locations representative of environments where these maize lines will be grown, over more than one 
season. The results of these evaluations indicate that nutritional contents of Bt11, MIR604 and GA21 
maize are not different to those for conventional maize. 
 
Additional studies were conducted to compare the composition of this stacked maize product 
containing Bt11, MIR604 and GA21 with relevant non-GM control maize lines. Commercial varieties 
were included in the comparison whenever possible. 
According to the updated EFSA guidance on risk assessment of food and feed from genetically 
modified plants (EFSA 2011a), there should be at least three appropriate non-GM reference varieties 
of the crop that have a known history of safe use at each site. The test of equivalence is used to verify 
whether the agronomic, phenotypic and compositional characteristics of the GM plant fall within the 
normal range of natural variation. Such a range of natural variation is estimated from a set of non-GM 
reference varieties with a history of safe use (EFSA 2011b) and therefore allows comparisons of the 
GM plant with a similar food or feed produced without the help of genetic modification and for which 
there is a well-established history of safe use. These requirements were however not in place at the 
time of submission.   
 
Bt11 x MIR604 x GA21 maize plants and the corresponding near-isogenic controls were grown at six 
locations in the North America for grain and forage analysis during the 2006 field trial season. At each 
location, the hybrids were grown in a randomized complete block design, with three replicates for 
each genotype. Sixty-five key food and feed nutrients, anti-nutrients and secondary plant metabolites 
(9 in forage, 56 in grain) were measured in the study, based on recommendations of the Organisation 
for Economic Co-operation and Development (OECD) for compositional considerations for new 
varieties of maize (OECD,2002). The data were subjected to analysis of variance across locations. 
Average levels of nutritional components were compared with the ranges of natural variation, as 
reported in the International Life Sciences Crop Composition database (ILSI 2006).  
 
All field trials were designed following a randomized complete block design with three replicate plots 
of each genotype. Data for each genotype were subjected to analysis of variance across locations. For 
each analyte the statistical significance of the genotype effect was determined using a standard F-test 
at the 5% probability. The significance of the location x genotype interaction was also assessed using 
an F-test. For some analytes location x genotype interactions were detected, suggesting that a certain 
degree of inconsistency existed across sites, therefore an analysis “per location” was also conducted. 
The results were compared to compositional analysis data for grain and forage published in the 
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literature and in compositional analysis databases. Moisture content of grain was not statistically 
analysed, because the grain had been mechanically dried. 
 
Details on the compositional analyses conducted with Bt11 x MIR604 x GA21 maize can be found in 
the technical dossier from the applicant (Appendix 4), considered confidential by Syngenta.  
 
 
3.2 Compositional Analysis 
 
The compositional parameters analysed for forage and grain of maize Bt11 x MIR604 x GA21 and its 
conventional counterpart are in line with those recommended by the OECD consensus document on 
key compositional parameters of maize (OECD, 2002). For some analytes, significant location-by-
genotype interactions suggested some degree of inconsistency among locations. In these cases 
genotype comparisons across locations may not be valid and no further conclusions were drawn 
regarding the overall genotype effect. However, the data were compared with the ILSI database to 
establish whether or not the ranges were within natural variation, as an indication of whether the 
results were likely to be of biological significance. 
 
3.2.1 Forage composition 
 
Forage from Bt11 x MIR604 x GA21 maize plants and the corresponding non-transgenic maize plants 
were analyzed for proximates (including acid detergent fiber (ADF) and neutral detergent fiber 
(NDF)), calcium and phosphorus. No statistically significant differences between genotypes were 
observed for any of the forage analytes measured. Average levels of all analytes measured in forage 
were within the ranges for conventional maize hybrids published by ILSI (2006).  
 
Proximates 
No statistically significant differences in moisture, protein, ash, carbohydrates, ADF and NDF were 
observed (Table 1 – appendix). A significant location-by genotype interaction was observed for fat. 
The mean levels of all proximates across locations and for each location were within the ranges 
reported in the ILSI database. 
 
Phosphorus and calcium 
The levels of phosphorus did not differ significantly between the two genotypes. A significant 
location-by-genotype interaction was observed for calcium. The mean levels of both minerals across 
locations and for each location were within the ranges reported in the ILSI database. 
 
3.2.2 Grain composition 
 
Grain was harvested after physiological maturity from Bt11 x MIR604 x GA21 maize and near-
isogenic control plants and analyzed for; proximates (ADF, NDF, TDF, starch, carbohydrates, protein, 
moisture, fat and ash), minerals (calcium, phosphorous, potassium, sodium, iron, copper, magnesium, 
manganese, selenium and zinc),  vitamins (Vitamins E, B1, B2, B3, B6, Folic Acid) and β−carotene, 
amino acids (eighteen amino acids were analysed), fatty acids (linoleic, oleic, palmitic, stearic and 
linolenic acids)  and secondary metabolites and anti-nutrients (furfural, phytic acid, inositol, trypsin 
inhibitor, raffinose, ferulic acid and p-coumaric acid). 
 
Of the 56 analytes measured in grain, statistically significant differences were noted for levels of 
protein, zinc and vitamin B1 and many of the amino acids (as expected from the difference in protein 
levels). For all the components measured in grain, the mean levels (across locations and at each 
location) were within the ranges of variation for conventional maize hybrids published in the ILSI 
database, except for vitamins B2 and E at some locations. Mean levels of vitamin B2 were slightly 
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higher than the published ranges at one of the six locations for the transgenic grain and one of the six 
locations for the non-transgenic grain. Vitamin E levels below the limit of quantitation occurred in 
samples of both the transgenic and non-transgenic grain at some locations. 
 
Proximates and fibers 
No statistically significant differences were observed in fat, carbohydrates, ADF, NDF, TDF and 
starch. However, a statistically significant difference in protein levels between the genotypes was 
observed. Further, a significant location-by genotype interaction were observed for ash. The mean 




The levels of copper, iron, magnesium, manganese, phosphorus, potassium, and selenium did not 
differ significantly between the two genotypes. Zinc levels were statistically significant different and a 
significant location by-genotype interaction was observed for calcium. For sodium, levels below the 
limit of quantitation (LOQ) precluded statistical analysis. Mean levels of all minerals across locations 
and for each location were within the ranges reported in the ILSI database. 
 
Amino acids 
Most of the amino acid levels differed significantly between the genotypes, a result consistent with the 
difference in protein levels . All mean amino acid levels across locations and for each location were 
within the ranges reported in the ILSI database. 
 
Fatty acids 
The proportion of the five most abundant fatty acids, as a fraction of total fatty acids did not differ 
significantly between the genotypes. All mean levels across locations and for each location were 
within the ranges reported in the ILSI database. 
 
Vitamins 
Levels of vitamins A, riboflavin (B2), niacin (B3), pyridoxine (B6), and folic acid (B9) did not differ 
significantly between the genotypes . A statistically significant difference was observed for thiamine 
(B1). For vitamin E, levels below the limit of quantitation (LOQ) precluded statistical analysis. All 
mean levels across locations and for each location were within the ranges reported in the ILSI database 
except for riboflavin (B2) levels, which were slightly higher in the transgenic grain at location 8 and in 
the non-transgenic grain at location 1, and the vitamin E levels that were <LOQ in both transgenic and 
non-transgenic grain at some locations. Below LOQ values for vitamin E are not represented in the 
ILSI database. 
 
Secondary metabolites and anti-nutrients 
There are no generally recognised anti-nutrients in maize at levels considered to be harmful, but for 
the purposes of assessment of substantial equivalence, the OECD has asked for analytical data for the 
following secondary metabolites in maize: ferulic acid, p-coumaric acid, furfural, inositol, phytic acid, 
raffinose and trypsin inhibitor. 
 
Levels of ferulic acid, p-coumaric acid, inositol, phytic acid, and trypsin inhibitor did not differ 
significantly between the genotypes. Levels of raffinose and furfural below the LOQ precluded 
statistical analysis. All mean levels across locations and for each location were within the ranges 
reported in the ILSI database. 
 
For most components measured in forage and grain, mean levels did not differ significantly between 
Bt11 x MIR604 x GA21 maize and non-transgenic maize. For all components except vitamin B2 and 
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vitamin E, mean levels across locations were within the ranges for conventional maize hybrids 
published in the ILSI Crop Composition Database.  
 
 
3.3 Agronomic and phenotypic characters  
 
During field trials over at ten locations in the USA in the 2006 growing season, data on phenotypic 
characteristics, agronomic performance (e.g., grain yield, number of emerged plants, plant population 
at harvest, plant height, ear height, root lodging) and disease susceptibility were collected for the 
maize stack Bt11 x MIR604 x GA21 and its conventional counterpart (near-isogenic conventional 
maize). Up to eighteen separate agronomic parameters and one disease trait were assessed at each 
location, although not all parameters were assessed at all locations. A list of the agronomic 
characteristics assessed and their descriptions are found in the Appendix 3 in the Technical Dossier.  
 
According to the applicant, the test locations were selected to be representative of the range of 
environmental conditions under which the tested hybrid varieties would typically be grown. Each of 
the agronomic trials was conducted as a randomized complete block design with five replications per 
location. For each agronomic or disease trait suitable for formal analysis, data were subjected to 
analysis of variance across locations. The statistical significance of the genotype effect (Bt11 x 
MIR604 x GA21 vs. the near-isogenic control) was determined using a standard F-test at the 5% 
probability. 
 
A statistical analysis on agronomic and phenotypic characteristics on a per-location basis was 
provided by the applicant at the EFSA GMO Panel’s request, complementing the across-location 
analysis already provided by the applicant. Analyses of variance across trial locations showed 
statistically significant differences between maize Bt11 x MIR604 x GA21 and the near-isogenic 
control hybrid for grain yield, grain moisture and plant height. The transgenic maize Bt11 x MIR604 x 
GA21 had significant higher yield compared the corresponding control at four of the ten sites (data not 
shown). According to the applicant the significant differences between the hybrids was likely due to 
the effects from specific locations where the hybrids were grown. Although insecticide was applied to 
both the control and the stacked hybrids at planting, insect pressure from the target pests European 
corn borer or corn rootworm in these locations may have caused damage to the control hybrids which 
may have contributed to the lower yields. The differences in the average values for plant height and 
grain moisture across locations were of minor magnitude. The statistical analysis showed additional 
statistically significant differences at individual field trial sites. However, when data from all locations 
were considered there were no consistent statistically significant differences that occurred in each 
separate location.  
 
Details on the agronomic and phenotypic characters can be found in the technical dossier from the 





Comparative analyses of data from field trials located at representative sites and environments in 
North America during the 2006 growing season indicate that maize stack Bt11 x MIR604 x GA21 is 
compositionally, agronomically and phenotypically equivalent to its conventional counterpart, with the 
exception of the insect resistance and the herbicide tolerance, conferred by the expression of Cry1Ab, 
mCry3A, PAT, PMI and mEPSPS proteins. 
 




EFSA/GMO/UK/2008/56 – Genetically modified maize Bt11 x MIR604 x GA21 
 
Based on the assessment of available data, the VKM GMO Panel is of the opinion that conventional 
crossing of maize Bt11, MIR604 and GA21 to produce the hybrid Bt11 x MIR604 x GA21 does not 
result in interactions between the newly expressed proteins affecting composition and agronomic 
characteristics.   
 
 
4 Food /feed risk assessment 
 
4.1. Summary of the previous evaluation of the single events  
 
The single maize events Bt11, MIR604 and GA21 have previously been evaluated by the VKM GMO 
Panel, and updated risk assessments were finalised in January 2014 (VKM 2014a,b,c). 
 
Maize Bt11  
Maize Bt11 has a long history of use, and has been evaluated extensively by The VKM GMO Panel. 
In the latest risk assessment (VKM 2014) it was concluded that Bt11 is nutritionally equivalent to 
conventional maize varieties and that it is unlikely that the Cry1Ab or PAT proteins will introduce a 
toxic or allergenic potential in food or feed based on maize Bt11 compared to conventional maize. 
 
With regard to animal studies with the whole product, feeding studies with maize Bt11 grain with 
different target animals, such as rats (Hammond et al 2006), broilers (Brake et al. 2003a) and laying 
hens, mice (Brake et al. 2004), dairy cows (Folmer et al. 2002) and beef cattle fed silage (Folmer et al. 
2002), have all indicated nutritional equivalence between maize Bt11 and its non-GM maize 
counterpart and to conventional maize (Chowdhury et al. 2003 a,b; 2004; Shimada et al 2006 a,b,c; 
2008). 
 
Furthermore, in a multi-generation study (5 generations) with ICR mice, performance and life span 
was investigated on mice fed diets containing 68% of either Bt11 maize or isogenic non-Bt maize. 
Multiple parameters were measured e.g. feed intake and growth, mating, gestation, milking periods, 
reproduction, longivety and pathology. No significant differences were found between the Bt11- and non-
Bt -fed mice in any of the generations (Haryu et al. 2009). 
 
Maize MIR604 
In the latest risk assessment of maize MIR604 the VKM GMO Panel concluded, based in part on data 
from whole food feeding studies on rats, rainbow trout and broilers, that maize MIR604 is 
nutritionally equivalent to conventional maize varieties. It is unlikely that the mCry3A or PMI proteins 
will introduce a toxic or allergenic potential in food or feed based on maize MIR604 compared to 
conventional maize. 
 
Maize GA21  
In the latest risk assessment of maize GA21 the VKM GMO Panel concluded, based in part on data 
from whole food feeding studies on rats, feedlot cattle and broilers, that maize GA21 is nutritionally 
equivalent to conventional maize varieties. It is unlikely that the mEPSPS protein will introduce a 
toxic or allergenic potential in food or feed based on maize GA21 compared to conventional maize. 
 
4.2 Product description and intended uses 
 
The scope of application EFSA-GMO-UK-2008-56 includes the import and processing of maize Bt11 
x MIR604 x GA21 and its derived products for use as food and feed. Thus, the possible uses of maize 
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Bt11 x MIR604 x GA21 include the production of animal feed, but it also includes valuable food 
products, such as starch, syrups and oils. The genetic modification of maize Bt11 x MIR604 x GA21 is 
intended to improve agronomic performance only and is not intended to influence the nutritional 
properties, processing characteristics and overall use of maize as a crop.  
 
4.3 Effects of processing 
 
There are two basic methods employed in processing field maize grain, dry milling and wet milling. In 
dry milling, maize is separated into flour, maize-meal, grits and other products. Wet milling is the 
process by which maize is separated into starch, germ to produce oil and fiber, and gluten for animal 
feed. Bt11xGA21 will be produced and processed in the same way as any field maize.  
 
The food manufacturing of Bt11 x MIR604 x GA21 field maize includes processing steps that are 
harsh, e.g. cooking, heating, high pressures, pH treatments, physical shearing, extrusion at high 
temperatures etc. under which the majority of proteins are denatured, which also applies to Cry1Ab1, 
PAT, mEPSPS, mCry3A and MIR604 PMI proteins (Hammond & Jez 2011). Concentrations of these 
proteins will be below the limit of detection in wet-milled fractions, in maize chips and maize oil. In 




4.4 Toxicological assessment 
 
4.4.1  Toxicological assessment of the newly expressed protein 
 
No new constituents other than the Cry1Ab, PAT, mEPSPS mCry3A and PMI proteins are expressed 
in maize Bt11 x MIR604 xGA21 and no relevant changes in the composition of maize Bt11 x MIR604 
x GA21 were detected by the compositional analysis. 
 
Following a request from the EFSA GMO Panel the applicant submitted an updated bioinformatics 
analysis comparing the amino acid sequences of the newly expressed proteins Cry1Ab, PAT, mCry3A, 
PMI and mEPSPS in maize Bt11 x MIR604 x GA21 with the sequences of known toxic and general 
proteins using an updated database. These analyses confirmed the results of the previous studies, 
which showed no similarities between the newly expressed proteins Cry1Ab, PAT, mCry3A, PMI and 
mEPSPS and known proteins toxic to mammals. 
 
Determination of the levels of the newly expressed proteins in grains of maize Bt11 x MIR604 x 
GA21, Bt11, MIR604 and GA21 showed comparable expression levels in the stacked maize events 
and the respective single maize events.  
 
 
4.4.2 Toxicological assessment of the whole GM food/feed 
 
49-day feeding study on broiler chickens 
Poultry studies are considered useful because chickens are fast growing organism that can consume 
large quantities of maize in the diet and thus are sensitive to potentially toxic effects of maize dietary 
components (OECD 2003).  
 
A 49-day poultry feeding study was conducted to evaluate whether standard poultry diets prepared 
with Bt11 x MIR604 x GA21 maize grain had any adverse effects on male or female broiler chickens 
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as compared to diets prepared with near isogenic control grain and other conventional maize lines 
commercially available. 
 
A broiler feeding study was conducted to compare the nutritional properties of maize MIR604 x GA21 
(NP2673(GA21)/ NP2171(BT11+MIR604) with its near-isogenic control NP2673/NP2171, and a 
locally grown commercial  maize NC 2007 (North Carolina, growing season 2006). One day old male 
(commercial strain Ross344) and female (commercial strain Ross 708) birds were distributed into 36 
pens assigned in a randomised complete block design. Male and female birds were housed separately. 
Each test group (GM, control, and reference) consisted of six replicated pens of 15 birds/gender, - a 
total of 540 birds. The birds were fed ad libitum the Starter diets from day 0 - 16, Grower diets from 
day 17 – 35, and Finisher diets from day 35-49.  
 
Three different diets: 1) Starter, 2) Grower, and 3) Finisher, were prepared for each of the three maize 
lines. Maize grain was mixed with soybean oil cake (48%) and other nutrients with an increasing 
inclusion of maize from starter to finisher diets (Table 1). 
 
Table 1. Composition of Starter, Grower and Finisher diets for the three maize lines tested. 
 
 NC 2007 Isogenic control Bt11 x MIR604 x GA21 
Ingredients Starter Grower Finisher Starter Grower Finisher Starter Grower Finisher 
Maize grain, % 51.10 57.97 63.32 49.55 55.72 60.87 49.23 56.36 60.48 
Soybean oil 
cake (48%), % 
38.72 31.46 26.49 37.78 30.49 25.43 37.95 30.67 25.63 
Other, % 10.18 10.57 10.19 12.67 13.79 13.7 12.82 12.97 13.89 
Total, % 100 100 100 100 100 100 100 100 100 
 
Animal performance on the various diets was evaluated by measuring mortality, body weight gain 
(overall final weight of males: 3359 g/animal; of females: 2764 g/animal), feed consumption, feed 
conversion ratio (FCR) (cumulative FCR of males 1.69 g/g; of females 1.77 g/g) and carcass yields 
(fat pad, drums, thighs, wings and breasts).  
 
At the end of the study feeding period, samples of the Bt11 x MIR604 x GA21 starting grain and the 
nontransgenic starting grain were analysed for the concentrations of Cry1Ab, PAT, mCry3A, MIR604 
PMI, and mEPSPS by ELISA. The Cry1Ab, PAT, mCry3A, MIR604 PMI, and mEPSPS proteins were 
not detected in the non-transgenic starting grain. The mean Cry1Ab concentration measured in the 
Bt11 x MIR604 x GA21 starting grain was 1.79 µg/g sample; the PAT concentration fell between the 
limit of detection (LOD; 0.02 µg/g grain) and the limit of quantitation (LOQ; 0.07 µg/g grain); the 
mCry3A concentration fell between the LOD (0.02 µg/g grain) and the LOQ (0.36 µg/g grain); the 
mean MIR604 PMI concentration was 2.59 µg/g sample; and the mean concentration of mEPSPS was 
3.91 µg/g sample. 
 
According to the applicant, there were no body weight differences among broilers consuming Bt11 x 
MIR604 x GA21 diets, non-transgenic diets, or NC 2007 diets. Further, there was no maize grain 
source-by-sex interaction for body weight. 
 
Broilers fed the Bt11 x MIR604 x GA21 diets had significantly improved feed conversion compared 
with broilers fed the NC 2007 diets during the 16-35 day and 0-35 day time periods while the broilers 
fed the non-transgenic diets performed intermediately between the two.  
 
The overall survival was good (>97%) and there were no differences between male and female 
broilers. There also were no significant effects between maize grain sources or maize grain source-by-
sex interactions. 
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The source of the maize grain had no effect on carcass yield (presented in either grams or as a 
percentage) among males or females. The yield of carcass portions was proportional to body weight 
for males and females in all cases. 
 
The broiler feeding study supported the results of the comparative compositional analysis and 
indicates that maize Bt11 x MIR604 x GA21 is nutritionally equivalent to grain from its conventional 
counterpart and a commercial non-GM maize variety when used in adjusted diets. 
 
4.5 Allergenicity assessment 
 
Most food allergies are mediated by immunoglobulin E (IgE, type-I reactions). The strategies used 
when assessing the potential allergenic risk focuses on the characterisation of the source of the 
recombinant protein, the potential of the newly expressed protein to induce sensitisation, or to elicit 
allergic reactions in already sensitised individuals and whether the transformation may have altered 
the allergenic properties of the modified food. A weight-of-evidence approach is recommended, taking 
into account all of the information obtained with various test methods, since no single experimental 
method yields decisive evidence for allergenicity (EFSA 2010).  
 
Most of the major food and respiratory IgE-allergens have been identified and cloned, and their 
protein sequences incorporated into various databases. As a result, novel proteins can be routinely 
screened for amino acid sequence homology and structural similarity to known human IgE-allergens 
using an array of bioinformatics tools. Sequence homology searches comparing the structure of novel 
proteins to known IgE-allergens in a database are conducted using various algorithms such as FASTA 
to predict overall structural similarities. According to FAO/WHO (2001) in cases where a novel 
protein and a known IgE-allergen have more than 35% identity over a segment of 80 or greater amino 
acids, IgE cross-reactivity between the novel protein and the allergen should be considered a 
possibility. 
 
4.5.1 Assessment of IgE-mediated allergenicity of the newly expressed protein 
 
A weighted risk analysis based on the decision tree approach has been performed by the applicant. The 
individual steps of this analysis comprise sequence homology to known allergens, specific or targeted 
serum screens for IgE cross-reactions to known allergens, digestability studies of the proteins in 
simulated gastric and/or intestinal fluids, and animal studies (FAO/WHO 2001; Codex Alimentarius 
2003; König et al. 2004; Poulsen 2004). 
 
The proteins Cry1Ab, PAT, mEPSPS, mCry3A and MIR604 PMI present in maize Bt11 x MIR604 x 
GA21 have been evaluated previously and it was found unlikely that they are allergenic.  
 
These assessments have previously been described by the applicant for the single maize events Bt11 
(Notification C/F/96/05.10 and EFSA-GMO-RX-Bt11), MIR604 (EFSA-GMO-2005-11) and GA21 
(EFSA-GMO-2005-19 and EFSA-GMO-RX-GA21), and were based on the following aspects:  
 
The proteins expressed by the transgenes in maize (Zea mays) are not considered common food 
allergens. 
 
Cry1Ab and PAT 
i) The sources of the transgene genes: B. thuringiensis (cry-genes) and S. viridochromogenes 
(pat) have no history of causing allergy 
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ii) History of safe use of Cry proteins as microbial pesticides (US EPA, 1998), no indications of 
Cry proteins originating from Bacillus thuringiensis having harmful effects on the health of 
humans and animals (US EPA, 1996).  
iii) The PAT protein has been subjected to previous safety assessments for genetically modified 
plants and found to have no allergenic potential  
iv) The PAT protein has no homology to known toxins or IgE-allergenic proteins  
v) The microbially produced Cry1Ab and PAT proteins were rapid degraded in simulated gastric 
fluids in vitro. No degradation assay in gastrointestinal fluids has been performed by the 
applicant. 
vi) PAT and Cry1Ab do not resemble any characteristics of known IgE-allergens, and no 
significant homologies between the amino acid sequences of the PAT and Cry1Ab proteins 
and IgE-allergenic proteins have been found (Fard et al, 2013, Kim et al, 2010, Randhawa et al 
2011, Meyer, 1999, US EPA, 2010).  
vii) The PAT and Cry1Ab protein are not glycosylated (Raybold et al, 2013, US EPA, 2010) 
viii) Cry1Ab and PAT are considered heat labile  (US EPA 2010) 
 
mEPSPS 
ix) The sources of the transgene gene is maize (Zea mays), which is not considered a common 
food allergen. 
x) EPSPS enzymes are ubiquitous in plants and microorganisms  
xi) A gene coding for the mEPSPS was expressed in bacteria and the resulting enzyme compared 
to the plant derived mEPSPS by Western blot. The enzymes expressed from the two sources 
were shown to be identical ( Raybould et al. 2013). 
xii) The mEPSPS is functionally equivalent to other food derived EPSPS enzymes except for its 
tolerance to Roundup® herbicides. 
xiii) The EPSPS proteins have been previously assessed for genetically modified plants and found 
to have no potential for allergenicity by EPA, Canadian Food Inspection Agency and OECD.  
xiv) The expressed mEPSPS protein is a single polypeptide with a 99.3 % sequence identity to the 
wild type. 
xv) The mEPSPS protein lacks homology to known toxins or allergenic proteins (Meyer, 1999; 
Cressman, 2003).  
xvi) Immunoblot glycosylation analyses of mEPSPS derived from recombinant E.coli and from 
extracts of leaf material from transgenic GA21 maize, indicate that both mEPSPS proteins are 
not glycosylated (Raybould et al. 2013). 
xvii) Rapid degradation of the mEPSPS protein in simulated gastric fluids in vitro (OECD, 1999). 
No degradation assay in gastrointestinal fluids has been performed by the applicant. 
xviii) The sources of the transgene genes: B. thuringiensis (cry-genes), E. coli (pmi),  and Zea mays 
(mepsps) have no history of causing allergy 
 
PMI 
i) PMI enzymes are found in various plants and microorganisms. 
ii) the pmi (manA) gene came from Escherichia coli, 
iii) the manA protein is a member of the superfamily of "cupins," which are proteins with a 
 specific 3-D structure. Some members of this super family are known allergens. 
iv) the gene coding for the PMI in the MIR604 was expressed in bacteria and the resulting 
 enzyme compared to the MIR604 derived PMI by Western blot. The enzymes expressed from 
the two sources were shown not to be identical, two amino acids were changed, valine-61 was 
substituted by alanine, and glutamine-210 by histidine. 
v) Bioinformatic analysis did not reveal any relevant sequence homology between the PMI 
expressed in maize MIR604 and known allergens of the cupin superfamily. 
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vi) No significant similarity was found between any of the PMI 80-amino acid peptides and any 
entries in the SBI Allergen Database. 
vii) In the eight or more contiguous amino acids homology search, there was an alignment 
 between the PMI protein and a recently identified allergen, α-parvalbumin from Rana species 
CH2001 (a frog of Indonesian origin). 
viii) Serum screening concluded that there is no cross-reactivity between PMI and serum IgE 
 (obtained from an allergic individual who displayed food-induce anaphylaxis from α-
 parvalbumin) 
ix) The PMI protein is rapidly degraded by simulated gastric fluids in vitro. No degradation assay 
in gastrointestinal fluids has been performed by the applicant 
x) The E. coli expressed PMI protein is also found in human intestinal microbiota, e.g. E. coli 
x) There has always been a background of human exposure and a low quantity of PMI found in 
the human diet. 
xi) The PMI-protein has been previously assessed in genetically modified plants and found to 
have no potential for allergenicity (EFSA 2009; Delany et al. 2008,).  
 
mCry3A 
The sources of the transgene mcry3A is Bacillus thuringiensis subsp.tenebrionis. A cry3A gene from 
Bt subsp. tenebrionis was recreated synthetically to optimize for expression in corn. The Cry3A 
protein from Bt subsp. tenebrionis is not considered a common food allergen. 
i) The expressed mCry3A protein is a single polypeptide with a 92.9 % sequence identity to the 
 wild type. 
ii) Immunoblot and glycosylation analysis of mCry3A derived from recombinant E.coli and from 
extracts of leaf material from transgenic MIR604 maize, indicate that post-translational 
glycosylation of mCry3A protein has not occurred. 
iii) A comparison of amino acid sequences of known allergens uncovered no evidence of any 
homology with mCry3A, even at the level of 8 contiguous amino acids residues. 
iv) The mCry3A protein is rapidly degraded by simulated gastric fluids in vitro. No degradation 
assay in gastrointestinal fluids has been performed by the applicant. 
v) At 4°C, 25°C, and 37° C there was little or no effect on mCry3A bioactivity, while at 65°C 
 there was some reduction in the bioactivity. At 95°C mCry3A protein was completely 
inactivated (US EPA 2010). 
 
4.5.2 Assessment of the IgE-mediated allergenicity of the whole GM plant 
 
Food allergies to maize are of low frequency and mainly occur in populations of specific geographic 
areas. Rare cases of occupational allergy to maize dust have been reported. There is no reason to 
expect that the use of maize Bt11 x MIR604 x GA21 will significantly increase the intake and 
exposure to maize. According to the applicant, a possible overexpression of any endogenous protein, 
which is not known to be allergenic, would be unlikely to alter the overall allergenicity of the whole 
plant or the allergy risk for consumers.  
 
However, an assessment of endogenous allergens in maize, ie mLTP (maize lipid transfer protein), has 
been carried out with immunoassays based on rabbit anti-mLPT-peptide serum (Panda et al, 2013). 
According to Panda et al. (2013) the intent of this study was to demonstrate that natural variation 
exists between varieties of commodity crops, demonstrating a 15-fold variation in mLTP 
concentration between nine maize varieties. The allergenicity assessment of GM plants is not meant to 
address the adventitious presence of an allergen in a given food but rather to understand whether a GM 
plant might be more allergenic than its non-GM comparator(s) to such an extent to be of concern for 
human and animal health (Fernandez et al. 2013). A major concern for the allergenicity assessment of 
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GM plants, however, is to evaluate whether the genetic modification introduces new allergens into the 
GM plant, and to verify that an increased expression of endogenous allergens in the GM plant has not 




According to the EFSA Opinion on the assessment of allergenicity of GM plants and microorganisms 
and derived food and feed (EFSA 2010) adjuvants are substances that, when co-administered with an 
antigen increase the immune response to the antigen and therefore might increase the allergic 
response. In cases when known functional aspects of the newly expressed protein or structural 
similarity to known strong adjuvants may indicate possible adjuvant activity, the possible role of these 
proteins as adjuvants should be considered. As for allergens, interactions with other constituents of the 
food matrix and/or processing may alter the structure and bioavailability of an adjuvant and thus 
modify its biological activity. 
 
Only two of the ~ 10 Cry proteins that are currently used in genetically modified plants, Cry1Ab and 
Cry1Ac, have been studied experimentally regarding adjuvant effects. To the knowledge of the VKM 
GMO Panel, adjuvant effects have not been investigated for the other Cry proteins normally used in 
GM plants, or other groups of Cry proteins.  
 
Studies with immunological mapping of the systemic and mucosal immune responses to Cry1Ac have 
shown that mice produce both systemic IgM and IgG and secretory IgA following intraperitonal (i.p.), 
intragastric (i.g.) or intranasal (i.n.) immunisation, and that the adjuvant effects of Cry1Ac is 
comparable to that of cholera toxin (CT) (Guerrero et al., 2004; Vazquez-Padron et al., 1999a, b; 
2000; Moreno-Fierros et al., 2003). The adjuvant effect of CT is thus a relevant basis for comparison 
in a risk assessment of Cry1Ac. It is uncertain whether this applies to the same extent to other Cry 
proteins. A possible immunogenicity and adjuvanticity of Cry proteins has been considered by EFSA 
and VKM (EFSA 2009, VKM 2012). 
 
“Bystander sensitisation” 
"Bystander sensitisation” can occur when an adjuvant in food, or an immune response against a food 
antigen, results in an increased permeability of the intestinal epithelium for other components in food. 
Traditionally it was assumed that the epithelial cells of the intestine were permanently "glued 
together" by the so-called "tight junctions". Studies have however shown that these complex protein 
structures are dynamic and that they can be opened up by different stimuli. 
Both in vitro and in vivo experiments have demonstrated that when an IgG response which can result 
in a complement activation (among other) is not balanced by an IgA response, the epithelial barrier 
can be opened and unwanted proteins are able to enter the body (bystander-penetration) and lead to 
allergic sensitisation (Brandtzaeg P, Tolo K 1977;  Lim PL, Rowley D1982). 
 
Additional information can be found in the report by VKM on Cry-proteins and adjuvanticity: “Health 
risk assessment of the adjuvant effects of Cry proteins from genetically modified plants used in food 
and fodder” (VKM 2012) 
 
4.6 Nutritional assessment of GM food/feed 
 
The broiler feeding study supported the results of the comparative compositional analysis, which 
showed that grain from maize Bt11 x MIR604 x GA21 is compositionally and, therefore, nutritionally 
equivalent to grain from the non-GM maize counterpart and conventional maize. The whole feed test 
indicates that no unexpected alterations in nutrients and other feed components have occurred and that 
no nutritional imbalances were introduced in Bt11 MIR604 xGA21. 
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4.6.1  Intake information/exposure assessment 
 
Net import of maize staple, e.g. flour, starch and mixed products, in Norway in 2007 was 7600 tons, 
corresponding to 4.4 g dry weight/person/day or an estimated daily energy intake for adults to be 0.6 
% (Vikse 2009). The estimated median daily intake of sweet maize is 3.25 g/day, with a 97,5 % 
percentile of 17.5 g/day. The production of maize porridge for children in 2007 was about 37.5 tons, 
corresponding to a daily intake of 1.7 g/day or an estimated daily energy intake to be 0.6 % for a 6 
month child (Vikse 2009).  
 
Since most foods and foodstuffs from maize are derived from field maize grains, an estimated 
maximum daily intake for a Norwegian adult of Cry1Ab, mCry3A, PAT, PMI and mEPSPS proteins 
from maize staple is calculated to be 8,36 µg, 2,64 µg, 7,04 µg, 21,56 µg and 31,24 µg, based on 
intake of maize staple (4.4 g/person/day) and the maximum protein levels in grain at physiological 
maturity in Table 1. The estimated maximum daily intake of Cry1Ab, mCry3A, PAT, PMI and 
mEPSPS proteins from sweet maize is calculated to be 33,25 µg, 28 µg, 10,5 µg, 85,75 µg and 124,25 
µg, respectively, based on a daily intake of 17.5 g fresh sweet maize/day (97.5 % percentile). These 
levels are several orders of magnitude below the levels shown to have no effect in laboratory 
toxicology testing. Also, these levels are considerably below the proposed threshold of toxicological 
concern (TTC) level of 1800 µg/person/day (Class 1, oral exposure) for chemicals considered to have 
a low potential for toxicity based on metabolism and mechanistic data (Vermeire et al., 2010). 
Transgenic proteins produced by genetically modified plants are generally considered non-toxic to 
humans.  
 
The VKM GMO Panel notes that farm (production) animals e.g. pigs and poultry often are fed diets 
with a substantial inclusion of unprocessed maize grain, and that the exposure to transgenic proteins 
from maize Bt11 x MIR604x GA21 may be higher for these animals. 
 
This dietary exposure assessment is very conservative as it assumes that all maize consumed comes 
from maize Bt11 x MIR604 x GA21 and that the transgenic proteins are not denatured by processing.  
 
 
4.5.2  Nutritional assessment of feed derived from the GM plant 
 
Based on the compositional analyses of forage and grain samples from maize Bt11 x MIR604 x GA21; 
nutritional equivalence to non-GM maize shown in a broiler feeding study; and evaluation of the 
transgenic proteins produced by the maize, maize Bt11 x MIR604 x GA21 and derived food and feed 
products seem to be substantially and nutritionally comparable to conventional maize and maize 




A whole food feeding study on broilers has not indicated any adverse health effects of maize Bt11 x 
MIR604 x GA21, and shows that maize Bt11 x MIR604 x GA21 is nutritionally equivalent to 
conventional maize. The Cry1Ab, PAT, mEPSPS, mCry3A or PMI proteins do not show sequence 
resemblance to other known toxins or IgE allergens, nor have they been reported to cause IgE 
mediated allergic reactions. Some studies have however indicated a potential role of Cry-proteins as 
adjuvants in allergic reactions. 
 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 x MIR604 x GA21 is 
nutritionally equivalent to conventional maize varieties. It is unlikely that the Cry1Ab, PAT, mEPSPS, 
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mCry3A or PMI proteins will introduce a toxic or allergenic potential in food or feed based on maize 
Bt11 x MIR604 x GA21 compared to conventional maize. 
 
 
5 Environmental risk assessment 
 
5.1 Unintended effects on plant fitness due to the genetic modification 
 
Maize (Zea mays L.) is an annual plant and member of the grass family Poacea. The species, 
originating from Central America, is highly domesticated and generally unable to survive in the 
environment without management intervention (Eastham & Sweet 2002).  Maize propagates entirely 
by seed produced predominantly by cross-pollination (OECD 2003). In contrast to weedy plants, 
maize has a pistillate inflorescence (ear) with a cob enclosed with husks. Due to the structure of the 
cob, the seeds remain on the cob after ripening and natural dissemination of the kernels rarely occurs.  
 
The survival of maize in Europe is limited by a combination of absence of a dormancy phase resulting 
in a short persistence, high temperature requirements for germination, low frost tolerance, low 
competitiveness and susceptibility to plant pathogens, herbivores and climatic conditions (van de Wiel 
et al. 2011). Maize plants cannot survive temperatures below 0ºC for more than 6 to 8 hours after the 
growing point is above ground  (OECD 2003), and in Norway and most of Europe, maize kernels and 
seedlings do not survive the winter cold (Gruber et al. 2008). Observations made on cobs, cob 
fragments or isolated grains shed in the field during harvesting indicate that grains may survive and 
overwinter in some regions in Europe, resulting in volunteers in subsequent crops. The occurrence of 
maize volunteers has been reported in Spain and other European regions (e.g. Gruber et al. 2008). 
However, maize volunteers have been shown to grow weakly and flower synchronously with the 
maize crop (Palaudelmás et al. 2009). Cross-pollination values recorded were extremely variable 
among volunteers, most probably due to the loss of hybrid vigour and uniformity. Overall cross-
pollination to adjacent plants was estimated as being low.  
 
Despite cultivation in many countries for centuries, seed-mediated establishment and survival of maize 
outside cultivation or on disturbed land in Europe is rare (BEETLE Report 2009). Maize plants 
occasionally grow in uncultivated fields and by roadsides. However the species is incapable of 
sustained reproduction outside agricultural areas in Europe and is non-invasive of natural habitats 
(Eastham & Sweet 2002; Devos et al. 2009). There are no native or introduced sexually cross-
compatible species in the European flora with which maize can hybridise and form backcross progeny 
(Eastham & Sweet 2002; OECD 2003). The only recipient plants that can be cross-fertilised by maize 
are other cultivated maize cultivars.  
 
It is considered very unlikely that the establishment, spread and survival of maize Bt11 x MIR604 x 
GA21 would be increased due to the insect resistance and herbicide tolerance traits. The herbicide 
tolerant trait can only be regarded as providing a selective advantage for the GM maize plant where 
and when glufosinate ammonium-based herbicides are applied. Glufosinate ammonium-containing 
herbicides have been withdrawn from the Norwegian market since 2008, and the substance will be 
phased out in the EU in 2017 for reasons of reproductive toxicity. Similarly insect resistance against 
certain lepidopteran and coleopteran pests provides a potential advantage in cultivation of Bt11 x 
MIR604 x GA21 under infestation conditions. It is considered very unlikely that maize Bt11 x 
MIR604 x GA21 plants or their progeny will differ from conventional maize cultivars in their ability 
to survive as volunteers until subsequent seasons, or to establish feral populations under European 
environmental conditions.  
 
Field trials carried out by the applicant do not indicate altered fitness of the single maize events Bt11, 
MIR604 and GA21 and the stacked event Bt11 x MIR604 x GA21 relative to its conventional 




EFSA/GMO/UK/2008/56 – Genetically modified maize Bt11 x MIR604 x GA21 
 
counterpart. A series of field trials with maize Bt11 x MIR604 x GA21 were carried out across ten 
locations in the USA in 2006.  Information on phenotypic (e.g. crop physiology, morphology, 
development) and agronomic (e.g. grain yield) characteristics was provided to assess the agronomic 
performance of maize Bt11 x MIR604 x GA21 in comparison with its conventional counterpart (see 
section 3.1). Data from these field trials showed some statistical significant differences for grain yield, 
grain moisture and plant height, and enhanced biomass production when glufosinate-ammonium/or 
glyphosate-based herbicides were applied and/or under infestation of target pests. These differences 
were however small in magnitude and were not consistently observed over locations. The VKM GMO 
Panel is of the opinion that they do not raise any environmental safety concern. No changes in plant 
characteristics indicating altered fitness and invasiveness of maize stack Bt11 x MIR604 x GA21 were 
observed. 
 
In addition to the data presented by the applicant, the VKM GMO Panel is not aware of any scientific 
reports indicative of increased establishment or spread of maize Bt11 x MIR604 x GA21, or changes 
to its survivability (including over-wintering), persistence or invasive capacity. Because the general 
characteristics of maize Bt11 x MIR604 x GA21 are unchanged, insect resistance, glufosinate and 
glyphosate tolerance are not likely to provide a selective advantage outside of cultivation in Europe. 
The VKM GMO Panel is of the opinion that the likelihood of unintended environmental effects based 
on establishment and survival of maize Bt11 x MIR604 x GA21 will not differ from that of 
conventional maize varieties. 
 
5.2  Potential for gene transfer 
 
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic material, 
either through horizontal gene transfer of DNA, or vertical gene flow via pollen or seed dispersal. 
Exposure of microorganisms to transgenic DNA occurs during decomposition of plant material 
remaining in the field after harvest or comes from pollen deposited on cultivated areas or the field 
margins. Transgenic DNA is also a component of a variety of food and feed products derived from 
maize Bt11 x MIR604 x GA21. This means that micro-organisms in the digestive tract in humans and 
animals (both domesticated animals and other animals feeding on fresh or decaying plant material 
from the transgenic maize line) may be exposed to transgenic DNA. 
 
Maize is the only representative of the genus Zea in Europe, and there are no cross-compatible wild or 
weedy relatives outside cultivation with which maize can hybridise and form backcross progeny 
(Eastham & Sweet 2002; OECD 2003). Vertical gene transfer in maize therefore depends on cross-
pollination with other conventional or organic maize varieties. All maize varieties which are cultivated 
in Europe can interbreed. In addition, unintended admixture/adventitious presences of genetically 
modified material/transgenes in seeds represent a possible way for gene flow between different 
production systems.  
 
 
5.2.1 Plant to micro-organisms gene transfer 
 
Experimental studies have shown that gene transfer from transgenic plants to bacteria rarely occurs 
under natural conditions and that such transfer depends on the presence of DNA sequence similarity 
between the DNA of the transgenic plant and the DNA of the bacterial recipient (Nielsen et al. 2000; 
De Vries & Wackernagel 2002, reviewed in EFSA 2004, 2009a; Bensasson et al. 2004; VKM 2005c). 
 
Based on established scientific knowledge of the barriers for gene transfer between unrelated species 
and the experimental research on horizontal transfer of genetic material from plants to 
microorganisms, there is today little evidence pointing to a likelihood of random transfer of the 
transgenes present in maize Bt11 x MIR604 x GA21 to unrelated species such as bacteria.   
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It is however pointed out that there are limitations in the methodology used in these experimental 
studies (Nielsen & Townsend 2004). Experimental studies of limited scale should be interpreted with 
caution given the scale differences between what can be experimental investigation and commercial 
plant cultivation.  
 
Experiments have been performed to study the stability and uptake of DNA from the intestinal tract in 
mice after M13 DNA was administered orally. The DNA introduced was detected in stool samples up 
to seven hours after feeding. Small amounts (<0.1%) could be traced in the blood vessels for a period 
of maximum 24 hours, and M13 DNA was found in the liver and spleen for up to 24 hours (Schubbert 
et al. 1994). By oral intake of genetically modified soybean it has been shown that DNA is more stable 
in the intestine of persons with colostomy compared to a control group (Netherwood et al. 2004). No 
GM DNA was detected in the faeces from the control group. Rizzi et al. (2012) provides an extensive 
review of the fate of feed-derived DNA in the gastrointestinal system of mammals.  
 
In conclusion, the VKM GMO Panel consider it is unlikely that the introduced gene from maize Bt11 
x MIR604 x GA21 will transfer and establish in the genome of microorganisms in the environment or 
in the intestinal tract of humans or animals. In the rare, but theoretically possible case of transfer of 
the cry, pat, pmi  and mepsps genes from Bt11 x MIR604 x GA21 to soil bacteria, no novel property 
would be introduced into or expressed in the soil microbial communities; as these genes are already 
present in other bacteria in soil. Therefore, no positive selective advantage that would not have been 
conferred by natural gene transfer between bacteria is expected. 
 
5.2.2 Plant to plant gene flow 
 
Considering the intended uses of maize Bt11 x MIR604 x GA21 (excluding cultivation) and the 
physical characteristics of maize seeds, possible pathways of gene dispersal are grain spillage and 
dispersal of pollen from potential transgenic maize plants originating from accidental grain spillage 
during transport and/or processing.  
 
The extent of cross-pollination to other maize cultivars will mainly depend on the scale of accidental 
release during transportation and processing, and on successful establishment and subsequent 
flowering of the maize plant. For maize, any vertical gene transfer is limited to other varieties of Zea 
mays plants as populations of sexually compatible wild relatives of maize are not known in Europe 
(OECD 2003). 
 
Survival of maize plants outside cultivation in Europe is mainly limited by a combination of low 
competitiveness, absence of a dormancy phase and susceptibility to plant pathogens, herbivores and 
frost. As for any other maize cultivars, GM maize plants would only survive in subsequent seasons in 
warmer regions of Europe and are not likely to establish feral populations under European 
environmental conditions. In Norway, maize plants from seed spillage occasionally grow on tips, 
waste ground and along roadsides (Lid & Lid 2005). 
 
The flowering of occasional feral GM maize plants origination from accidental release during 
transportation and processing is however unlikely to disperse significant amounts of GM maize pollen 
to other maize plants. Field observations performed on maize volunteers after GM maize cultivation in 
Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that cross-
pollinated neighbour plants only at low levels (Palaudelmás et al. 2009).  
 
As maize Bt11 x MIR604 x GA21 has no altered survival, multiplication or dissemination 
characteristics, the VKM GMO Panel is of the opinion that the likelihood of unintended environmental 
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effects as a consequence of spread of genes from this GM maize in Norway will not differ from that of 
conventional maize varieties. The likelihood of cross-pollination between cultivated maize and the 
occasional feral maize plants resulting from grain spillage is considered extremely low. 
 
5.3 Interactions between the GM plant and target organisms 
 
Considering the intended uses of maize Bt11 x MIR604 x GA21, excluding cultivation, the 
environmental exposure is limited to exposure through manure and faeces from the gastrointestinal 
tract mainly of animals fed on the GM maize as well as to the accidental release into the environment 
of GM seeds during transportation and processing and subsequently to potential occurrence of 
sporadic feral plants. Thus the level of exposure of target organisms to Cry1Ab and mCry3Aproteins 
is likely to be extremely low and of no ecological relevance. 
 
 
5.4 Interactions between the GM plant and non-target organisms (NTOs) 
 
Considering the intended uses of maize stack Bt11 x MIR604 x GA21, excluding cultivation, the 
environmental risk assessment is concerned with accidental release of GM maize viable grains into the 
environment during transportation and processing, and exposure through manure and faeces from the 
gastrointestinal tracts of animals fed the GM maize.  
 
Cry proteins are degraded by enzymatic activity in the gastrointestinal tract, meaning that only very 
low amounts would remain intact to pass out in faeces (e.g. Lutz et al. 2005, Guertler et al. 2008; Paul 
et al. 2010).  There would subsequently, be further degradation of the Cry proteins in the manure and 
faeces due to microbial processes. In addition, there will be further degradation of Cry proteins in soil, 
reducing the possibility for the exposure of potentially sensitive non-target organisms. Although Cry 
proteins bind rapidly on clays and humic substances in the soil and thereby reducing their availability 
to microorganisms for degradation, there is little evidence for the accumulation of Cry proteins from 
GM plants in soil (Icoz & Stotzky 2009). 
 
Data supplied by the applicant indicate that a limited amount of the Cry1Ab and mCry3A proteins 
enters the environment due to expression in the grains (mean value of 1.6 and 3.1 µg/g d.w., 
respectively). In addition, the data show that at least 99% of microbially produced Cry1Ab and 
mCry3A proteins were rapidly degraded in simulated gastric fluid.  
 
In conclusion, the VKM GMO Panel considers that the exposure of potentially non-target organisms 
to the Cry1Ab and mCry3A proteins is likely to be very low and of no ecological relevance. 
 
 
5.5 Potential interactions with the abiotic environment and biochemical 
cycles 
 
Considering the intended uses of maize Bt11 x MIR604 x GA21, which exclude cultivation, and the 
low level of exposure to the environment, potential interactions of the GM plant with the abiotic 




The scope of the application EFSA/GMO/UK/2008/56 includes import and processing of maize Bt11 
x MIR604 x GA21 for food and feed uses. Considering the intended uses of maize Bt11 x MIR604 x 
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GA21, excluding cultivation, the environmental risk assessment is concerned with accidental release 
into the environment of viable grains during transportation and processing, and indirect exposure, 
mainly through manure and faeces from animals fed grains from maize Bt11 x MIR604 x GA21.  
 
Maize Bt11 x MIR604 x GA21 has no altered survival, multiplication or dissemination characteristics, 
and there are no indications of an increased likelihood of spread and establishment of feral maize 
plants in the case of accidental release into the environment of seeds from maize Bt11 x MIR604 x 
GA21. Maize is the only representative of the genus Zea in Europe, and there are no cross-compatible 
wild or weedy relatives outside cultivation. The risk of gene flow from occasional feral GM maize 
plants to conventional maize varieties is negligible. Considering the intended use as food and feed, 
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6 Data gaps  
 
Adjuvanticity   
 
There are many knowledge gaps related to assessment of adjuvants. Most of the immunologic 
adjuvant experiments have been performed using Cry1Ac. Whether the other Cry proteins have similar 
adjuvant properties is unknown.  
 
The quantities of Cry proteins in genetically modified maize and soya are marginal compared with the 
amounts of other adjuvants that are natural components of food. However, the extent to which these 
naturally occurring adjuvants and Cry proteins contribute to the development of allergies is largely 
unknown. Determination of their importance is hampered by the lack of validated methods for 
measuring adjuvant effects.  
 
The possibility that Cry proteins might increase the permeability of the intestinal epithelium and 
thereby lead to "bystander" sensitization to strong allergens in the diet of genetically susceptible 
individuals cannot be completely excluded. This possibility could be explored in a relevant animal 
model.  
 
One element of uncertainty in exposure assessment is the lack of knowledge concerning exposure via 
the respiratory tract and the skin, and also the lack of quantitative understanding of the relationship 
between the extent of exposure to an adjuvant and its effects in terms of development of allergies. 
 
Herbicide residue levels  
Herbicide residue levels on plants with engineered resistance to one or two broad spectrum herbicides 
could entail higher levels of herbicide residue cocktails compared to plants produced by conventional 
farming practice. 
 
Since it is difficult to predict the toxicity of cocktails from the toxicity of the single components, there 
is uncertainty related to risk of confounding effects such as additive or synergistic effects between the 
residues in herbicide resistant plants.   
 
The transgene technology used can possibly lead to different metabolic products of the applied 
herbicides from what is expected from conventional usage. The risk assessment of herbicides 
should take into account plants with altered metabolism.  
 
At present the changes related to herbicide residues of stacked plants as a result of the application 

















Molecular characterisation  
Southern blot and PCR analyses have indicated that the recombinant inserts in the parental maize lines 
Bt11, MIR604 and GA21 are retained in the stacked maize Bt11 x MIR604 x GA21. Genetic stability 
of the inserts has previously been demonstrated in the parental maize lines. Protein levels measured by 
ELISA show comparable levels of the Cry1Ab, PAT, mCry3A, PMI and mEPSPS proteins between 
the stacked and single maize lines. Phenotypic analyses also indicate stability of the insect resistance 
and herbicide tolerance traits in the stacked maize. The VKM Panel on GMO considers the molecular 




Comparative analyses of data from field trials located at representative sites and environments in 
North America during the 2006 growing season indicate that maize stack Bt11 x MIR604 x GA21 is 
compositionally, agronomically and phenotypically equivalent to its conventional counterpart, with the 
exception of the insect resistance and the herbicide tolerance, conferred by the expression of Cry1Ab, 
mCry3A, PAT, PMI and mEPSPS proteins. 
 
Based on the assessment of available data, the VKM GMO Panel is of the opinion that conventional 
crossing of maize Bt11, MIR604 and GA21 to produce the hybrid Bt11 x MIR604 x GA21 does not 
result in interactions between the newly expressed proteins affecting composition and agronomic 
characteristics.   
 
Food and feed risk assessment 
A whole food feeding study on broilers has not indicated any adverse health effects of maize Bt11 x 
MIR604 x GA21, and shows that maize Bt11 x MIR604 x GA21 is nutritionally equivalent to 
conventional maize. The Cry1Ab, PAT, mEPSPS, mCry3A or PMI proteins do not show sequence 
resemblance to other known toxins or IgE allergens, nor have they been reported to cause IgE 
mediated allergic reactions. Some studies have however indicated a potential role of Cry-proteins as 
adjuvants in allergic reactions. 
 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 x MIR604 x GA21 is 
nutritionally equivalent to conventional maize varieties. It is unlikely that the Cry1Ab, PAT, mEPSPS, 
mCry3A or PMI proteins will introduce a toxic or allergenic potential in food or feed based on maize 
Bt11 x MIR604 x GA21 compared to conventional maize. 
 
Environmental risk assessment 
The scope of the application EFSA/GMO/UK/2008/56 includes import and processing of maize stack 
Bt11 x MIR604 x GA21 for food and feed uses. Considering the intended uses of maize Bt11 x 
MIR604 x GA21, excluding cultivation, the environmental risk assessment is concerned with 
accidental release into the environment of viable grains during transportation and processing, and 
indirect exposure, mainly through manure and faeces from animals fed grains from maize Bt11 x 
MIR604 x GA21.  
 
Maize Bt11 x MIR604 x GA21 has no altered survival, multiplication or dissemination characteristics, 
and there are no indications of an increased likelihood of spread and establishment of feral maize 
plants in the case of accidental release into the environment of seeds from maize GA21. Maize is the 
only representative of the genus Zea in Europe, and there are no cross-compatible wild or weedy 
relatives outside cultivation. The VKM GMO Panel considers the risk of gene flow from occasional 
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feral GM maize plants to conventional maize varieties to be negligible in Norway. Considering the 
intended use as food and feed, interactions with the biotic and abiotic environment are not considered 
by the GMO Panel to be an issue. 
 
Overall conclusion 
Based on current knowledge, the VKM GMO Panel concludes that maize Bt11 x MIR604 x GA21 is 
nutritionally equivalent to conventional maize varieties. It is unlikely that the Cry1Ab, PAT, mEPSPS, 
mCry3A or PMI proteins will introduce a toxic or allergenic potential in food or feed based on maize 
Bt11 x MIR604 x GA21 compared to conventional maize. 
 
The VKM GMO Panel likewise concludes that maize Bt11 x MIR604 x GA21, based on current 
knowledge, is comparable to conventional maize varieties concerning environmental risk in Norway 
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